Document:

Exhibit 10.1

 

Share
PURCHASE AGREEMENT

 

This
Share Purchase Agreement (this “Agreement”) is entered into as of December 18, 2022, by and among:

 

		(i)	Titan
                                            Innovations Ltd., an Israeli corporation, having its registered office at 26 Maskit St.,
                                            Herzliya, Israel (“Purchaser”);

 

		(ii)	Sky
                                            Sovereign Inc, a US company registered under the laws of Nevada and a wholly owned subsidiary
                                            of the Parent (as defined below), with its registered office at 5000 Quorum Drive, Dallas,
                                            TX 75254, USA (“Seller”);

 

		(iii)	COMSovereign
                                            Holding Corp., a US public company registered under the laws of the state of Nevada, with
                                            its registered office at 5000 Quorum Drive, Dallas, TX 75254, USA (“Parent”);

 

		(iv)	Sky
                                            Sapience Ltd., an Israeli company R.N. 514382829 (the “Company”).

 

(the
Purchaser, the Seller and the Company may be addressed hereto as the “Parties” or each one alone the “Party”).

 

R
E C I T A L S

 

WHEREAS,
the Seller owns all the share capital of the Company on a Fully Diluted Basis1;

 

WHEREAS,
the Purchaser is entering into this Agreement in order to acquire, at Closing, all of the Company’s issued and outstanding share
capital on a Fully Diluted Basis immediately prior to Closing and upon the Closing (the “Company Shares”), (under
the terms set forth below in this Agreement;

 

WHEREAS,
the Seller desires to sell to Purchaser, and Purchaser desires to purchase all of the Company Shares held by Seller on the terms and
conditions set forth in this Agreement, subject to the terms and conditions of this Agreement (the “Transactions”);

 

 

		1	“Fully
Diluted Basis” the corporation’s share capital on a fully diluted as-converted basis, including all shares (whether
ordinary shares, preferred shares, or otherwise) which are issued, as well as all shares issuable assuming the exercise, conversion or
exchange into shares of all warrants, options, notes, debentures, or other rights, securities, agreements or other commitments which
by their terms are exchangeable, exercisable or convertible (taking into account anti-dilution or other similar rights), directly or
indirectly, for or into share capital of the corporation, whether or not vested, and whether outstanding, promised or contingent (with
such securities being calculated on an as-exercised, as-converted and as-exchangeable basis), and all shares reserved for issuance to
the corporation’s and its subsidiaries’ employees, consultants, service providers and directors under the corporation’s
share option/incentive plans and arrangements, whether or not any options thereunder are then outstanding or promised.

 

    1

     

    

  

A
G R E E M E N T

 

Now,
therefore, in consideration of the mutual agreements
and undertakings set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the Parties hereto, intending to be legally bound, agree as follows:

 

Article
1

SALE AND PURCHASE OF SHARES

 

1.1 Purchase
and Sale of Company Shares.

 

Subject
to the terms and conditions set forth herein, at the Closing, the Purchaser will acquire the Company Shares held by the Seller for cash
consideration as follows:

 

(i) the
Seller shall sell, assign, transfer and convey to the Purchaser all of the Company Shares free and clear of all Encumbrances2;

 

(ii) the
Seller shall deliver to Purchaser a share certificate (the “Certificate”) (or Affidavit) representing the Company
Shares, together with a duly executed share transfer deed with respect to the Company Shares in the form attached hereto as Exhibit
A;

 

(iii) the
Purchaser shall purchase all of the Company Shares from the Seller;

 

(iv) The
Purchaser shall deposit:

 

(a)
an amount of USD 400,000 out of the Purchase Price, (the “First Escrow Amount”), by wire transfer of immediately
available funds to the Escrow Agent, to be transferred and held in accordance with the terms, including timeline, of this Agreement and
the Escrow Agreement by and among the Purchaser, the Seller, and the Escrow Agent in the form of Exhibit B attached hereto
(the “Escrow Agreement”); (b) an amount of USD 350,000 out of the Purchase Price, (the “Second
Escrow Amount”), by wire transfer to the Escrow Agent, to be transferred and held in accordance with the terms of this
Agreement and the Escrow Agreement; (c) an amount of USD 450,000 (the “Payment Agent Amount”) to the Payment
Agent, to be transferred and held in accordance with the terms, including timeline, of this Agreement and the Payment Agent Agreement
by and among the Purchaser, the Seller, and the Payment Agent substantially in the form of Exhibit B1 attached hereto (the
“Payment Agent Agreement”). Payment of the Escrow Amounts and the Payment Agent Amount (together the “Purchase
Price”) as aforesaid shall constitute for all purposes herein payment to the Seller for the sale of the Company Shares.

 

 

		2	“Encumbrance”
                                            means any claim, charge, community property interest, lease, covenant, easement, encumbrance,
                                            security interest, mortgage, lien, option, pledge, condition, equitable interest, encroachment,
                                            right of way, right of first refusal or other rights of others, or restriction of any kind
                                            (whether on voting, sale, transfer, disposition or otherwise), whether imposed by agreement,
                                            understanding, law, equity or otherwise, except for any restrictions on transfer generally
                                            arising under any applicable federal or state securities law, but excluding any encumbrance,
                                            restriction or limitation imposed by the Transaction Documents themselves.

 

    2

     

    

 

As
soon as reasonably practicable after Purchaser makes the wire of each Escrow Amount and the Payment Agent Amount to the Escrow Agent
and the Payment Agent (respectively), Purchaser shall provide the Seller and the Escrow Agent/Payment Agent with a copy of the wire transfer
confirmation issued by the originating bank through which Purchaser effected such payment(s).

 

1.2 Sale
of Systems.

 

At
the Closing, the Purchaser shall purchase from the Seller, and the Seller shall sell to the Purchaser, as part of the Purchase Price,
the systems detailed in Schedule ‎1.2, which are located in the U.S. (one in Arizona and one in Florida). Following
the Closing, if so requested by Purchaser, the Seller and Parent will reasonably assist for those systems to be shipped to Israel, including
applying all reasonable efforts with regards to filings required with the US government for the shipment of such systems. It is clarified
that the export of the systems from the U.S. to Israel will be on the name of the Purchaser and at Purchaser’s sole cost. Seller and
Parent make no warranties regarding the systems, except that they are duly kept in storage in the aforementioned states as evidenced
by pictures or video footage of the systems to be sent to Purchaser prior to shipment, and further make no representation or warranties
regarding the availability of any permits, licenses, or the like, to allow Purchaser to export the systems from the U.S. to Israel.

 

1.3 Payment
Agent.

 

The
Purchaser shall appoint ESOP Management and Trust Services Ltd., to act in two different capacities under this Agreement: as the payment
agent (the “Payment Agent”), pursuant to the Payment Agent Agreement and the escrow agent (the “Escrow
Agent”), pursuant to the Escrow Agreement, with the costs and expenses of such arrangements to be borne by the Purchaser.
(i) At the Pre-Closing (as defined below), the Purchaser shall deliver to the Escrow Agent the First Escrow Amount. (ii) within
2 weeks from the wire of the First Escrow Amount, the Purchaser shall deliver to the Escrow Agent the Second Escrow Amount. (iii)
At the Closing, the Purchaser shall deliver to the Payment Agent the Payment Agent Amount. Out of the Purchase Price, the Escrow
Amounts will be directed towards payment of all of Company’s debt subject to and in accordance with the terms of the Escrow Agreement.
The remainder (meaning the Payment Agent Amount) shall be transferred by the Payment Agent to the Seller in accordance with the terms
of the Payment Agent Agreement. If the amounts to be paid from the Escrow Amount to debtors include VAT, the payees of the Escrow Amount
shall issue applicable invoices to the Company, the Company will duly file for VAT return to the VAT authority, and when such VAT return
is received by Purchaser, the Purchaser shall wire transfer of immediately available funds to the Payment Agent, for payment to the Seller
in accordance with the Payment Agent Agreement, an amount equal to any VAT amount returned to the Company on account of such payments.

 

    3

     

    

 

Article
2

THE CLOSING

 

2.1 Time
and Place of Closing. Subject to the terms and conditions of this Agreement, the closing of the Transaction of this Agreement
(the “Closing”) shall occur remotely, on such date and time as the Parties may agree upon, but not later than
3 days following the completion of all closing conditions set forth in Article 7 and Article 8 (the “Closing Date”).
The Parties agree that any Party may, for purposes of the Closing, deliver electronically such documents, certificates or other instruments
required to be delivered pursuant to this Agreement. All of the actions, transactions and deliveries to occur at the Closing as listed
in Section ‎2.2 and ‎2.3 below will be deemed to have been taken, occurred or been delivered simultaneously and no action,
transaction or delivery shall be deemed to have occurred or been delivered, unless and until all such actions and transactions have been
completed and such deliveries made (unless waived in writing by the applicable Party).

 

2.1(A)
Time and Place of Pre-Closing. Subject to the terms and conditions of this Agreement, the pre-closing phase of the Transaction
of this Agreement (the “Pre-Closing”) shall occur remotely,
on such date and time as the Parties may agree upon, but not later than 3 days following the completion of all closing conditions set
forth in Article 7A and Article 8 (the “Pre-Closing Date”). The Parties agree that any Party may, for purposes
of the Pre-Closing, deliver electronically such documents, certificates or other instruments required to be delivered pursuant to this
Agreement. All of the actions, transactions and deliveries to occur at the Closing as listed in Section ‎2.2(A) and ‎2.3(A)
below will be deemed to have been taken, occurred or been delivered simultaneously and no action, transaction or delivery shall be
deemed to have occurred or been delivered, unless and until all such actions and transactions have been completed and such deliveries
made (unless waived in writing by the applicable Party).

 

2.2 Closing
Deliveries by Company and Seller. At the Closing, the Company and the Seller shall deliver the following items, duly executed by
their intended signatory, all of which shall be in the applicable form attached hereto:

 

(a) Unanimous
written resolutions of the both the Company’s and Seller’s board of directors and of the Company’s sole shareholder
authorizing the execution, delivery and performance of this Agreement and all other Transaction Documents3; It is agreed
that these resolutions shall be provided by the Seller to the Purchaser concurrently with the execution of this Agreement.

 

(b) Certificate
representing the Company Shares to be sold to Purchaser at the Closing, which represents the remaining 59% of the Company Shares to be
transferred to the Purchaser, in the form attached hereto as Schedule ‎2.2(b),
accompanied by duly executed share transfer deed, representing such 59% of the Company Shares;

 

If
any share certificate shall have been lost, stolen or destroyed or never issued, then, instead of such certificate, the Seller shall
provide to the Purchaser an affidavit of that fact (an “Affidavit”).

 

(c) The
shareholders register updated to reflect the sale of all of the Company Shares in the form attached hereto as Schedule ‎2.2(c)(i),
plus share certificates representing the shares to be held by the Purchaser upon Closing in the form attached hereto as Schedule
‎2.2(c)(ii).

 

 

		3	“Transaction
                                            Documents” means this Agreement and all documents, agreements, instruments
                                            and certificates executed and delivered in connection with the Closing, this Agreement and
                                            the transactions contemplated hereunder.

 

    4

     

    

  

(d) All
acknowledgements, approvals and consents listed on Schedule ‎2.2(d).

 

(e) An
opinion, dated as of the Closing Date, from Fischer (FBC & Co.), the Company’s legal counsel, in the form attached as Exhibit
C hereto, and a certification, dated as of the Closing Date, from the Parent’s and Seller’s US legal counsel, in
the form attached as Exhibit C1 hereto.

 

(f) A
certificate signed by the CEO, Joshua “Shuki” Rynski of the Company in the form attached hereto as Schedule 
‎2.2(f) that:

 

(i) Confirms
that the articles of association of the Company as in effect as of the Closing Date are the articles attached to such certificate.

 

(ii) Confirms
the duly adoption of: (a) unanimous written resolutions of the Company’s board of directors and (b) unanimous written resolution
of the sole shareholder of the Company authorizing the execution, delivery and performance of this Agreement, and all other Transaction
Documents;

 

(iii) Confirming
the absence of any Material Adverse Effect4 in the Company for the period between the date of signing this Agreement and
the Closing Date.

 

(iv) Confirming
that the representations and warranties of the Company made under Article 4 are true and correct in all material respects as of the date
of the Closing with the same effect as though made on and as of the date of the Closing, except that representations and warranties which
are qualified by a materiality qualification which shall be true and correct in all respects.

 

(v) Confirming
that the Company has performed and complied, in all material respects, with all of the covenants, agreements, undertakings and conditions
required to be performed and/or complied with at or prior to the Closing in all respects; and

 

 

		4	“Material
Adverse Effect” means with respect to the Company, any event, occurrence, change or effect that, when taken individually
or together with all other adverse events, occurrences, changes and effects, has resulted or is reasonably likely (a) to be materially
adverse to the condition (financial or otherwise), properties, assets, liabilities, business, operations or results of operations of
the Company (taken as a whole) except to the extent any events, occurrences, changes and effects results from or is attributable to (i)
changes in general economic conditions (provided that such change does not impact the Company in a disproportionate manner);
(ii) changes affecting the industry in which the Company operate generally (provided that such change does not impact the Company
in a disproportionate manner); (iii) any act of war, or terrorism or any military action but only to the extent that they do not
have a disproportionate impact on the Company relative to other Persons in the applicable geographical area; (iv) changes in applicable
Laws or GAAP, or (b) to prevent or materially delay the consummation of the Transactions or otherwise prevent the Company, Sellers from
performing its obligations under this Agreement.

 

    5

     

    

  

(vi) Confirming
that the Company has obtained any and all consents, permits and waivers necessary for consummation of the transactions contemplated by
this Agreement as detailed in Section ‎7.2.

 

(g) A
certificate of good standing (that the Company is not a “law violating company” pursuant to the records of the Registrar
of Companies).

 

(h)Duly
executed copies of the Employment Agreement in substantially the form of Exhibit D, (collectively, the “Purchaser
Employment Package”), to become effective upon the Closing, signed by Ethan Chamlevski (the “Key Employee”)
on the one hand, and the Company, on the other hand;

 

(i) The
resignation of each director and officer of the Company who is listed in Exhibit E hereto effective as of the Closing Date.

 

(j) The
Payment Agent Agreement duly executed by the Seller.

 

(k) The
Escrow Agreement duly executed by the Escrow Agent and the Seller.

 

(l) Such
other certificates, documents or instruments as may reasonably be requested by Purchaser in order to ensure the validity of the Transactions
contemplated by this Agreement.

 

(m) The
Charge Agreements duly executed by the Company and the Seller.

 

2.2(A) Pre-Closing
Deliveries by Company and Seller. At the Pre-Closing, the Company and the Seller shall deliver the following items, duly executed
by their intended signatory, all of which shall be in the applicable form attached hereto:

 

(a) The
items specified in Sections ‎2.2(a), ‎2.2(d), ‎2.2(e), ‎2.2(f), ‎2.2(g), ‎2.2(h),
‎2.2(i), ‎2.2(j) and ‎2.2(k);

 

(b) (i)
a certificate representing 22% of the Company Shares to be transferred to the Purchaser free and clear of any Encumbrance at the Pre-Closing
in the form attached hereto as Schedule ‎2.2(b), accompanied
by duly executed share transfer deed, representing such 22% of the Company Shares; and (ii) a certificate representing 19% of the Company
Shares to be transferred to the Purchaser free and clear of any Encumbrance at upon the release by the Escrow Agent of the Second Escrow
Amount in accordance with the Escrow Agreement, accompanied by duly executed share transfer deed, representing such 19% of the Company
Shares.

 

(c) The
shareholders register updated to reflect the transfer of such 22% and thereafter such 19% of the Company Shares in the form attached
hereto as Schedule 2.2(A)(c).

 

It
is clarified that the share certificates, share transfer deeds and shareholders registries, will be held by the Escrow Agent, pending
its release to the Purchaser in accordance with the Escrow Agreement.

 

    6

     

    

 

2.3 Closing
Deliveries by Purchaser. At the Closing, Purchaser shall deliver to the Company and the Seller:

  

(a) written
confirmation from the Payment Agent of the receipt of payments and deposits as contemplated by Section ‎1.1;

 

(b) copy
of the Payment Agent Agreement, duly executed by Purchaser and the Payment Agent;

 

(c) copy
of the Escrow Agreement, duly executed by Purchaser;

 

(d) copy
of shareholders resolution of the Company appointing new director(s) to the board of directors on behalf of the Purchaser and amending
the Company’s signature rights;

 

(e) copy
of the Charge Agreements, duly executed by Purchaser.

 

2.3(A) Pre-Closing
Deliveries by Purchaser. At the Pre-Closing, Purchaser shall deliver to the Company:

 

(a) written
confirmation from the Escrow Agent of the receipt of payment and deposit as contemplated by Section ‎1.1(iv)(a);

 

(b) The
items specified in Sections ‎2.3(b) and ‎2.3(c);

 

2.4 Payment
of the 600,000 Payment. Additional consideration in the amount of USD 600,000 (the “600,000 Payment”)
plus annual interest of US Prime + 2%, shall be transferred by the Purchaser to the Payment Agent for disbursement to the Seller within
24 months of Closing, in one or more installments. At the Closing, the Parties will execute, deliver and, right after the Closing file
with the Israeli Registrar of Companies, the USPTO and UCC, charge agreement over the Company’s Intellectual Property, such charge
to be removed only after the payment by the Purchaser to the Seller of the 600,000 Payment, less any debts that will be paid out of the
600,000 Payment pursuant to the terms of this Agreement (the “Charge Agreements”). The Cost of the Charge Agreements
will be paid 50% by each of the Seller and Purchaser.

 

Article
3

REPRESENTATIONS AND WARRANTIES of the Seller

 

3.1 Except
as otherwise indicated in the Disclosure Schedule5, the Seller represents and warrants to Purchaser, as of the date
of this Agreement and as of the Closing and acknowledges and confirms that the Purchaser is relying upon such representations and warranties
in entering into this Agreement, as follows:

 

3.2 Organization
and Qualifications. The Seller represents and warrants that it is duly organized validly existing under the Laws of the state
indicated in Schedule ‎3.2, and is in good standing (where such concept is recognized) (and is not in any insolvency or liquidation
proceedings – where such concept is not recognized), and has all requisite power and authority to own the Company Shares.

  

 

		5	“Disclosure
Schedule” means the Disclosure Schedules attached hereto.

 

    7

     

    

  

3.3 Authority;
Enforceability. The Seller has the legal capacity and all necessary power and authority to execute and deliver this Agreement and
the other Transaction Documents to which it is a party, to perform its obligations hereunder and thereunder, and to consummate the Transactions
contemplated hereby and thereby. The execution and delivery of this Agreement and the other Transaction Documents and the consummation
by the Seller of the Transactions has been duly and validly authorized by all requisite actions including any shareholder vote, as applicable,
and no other proceedings on the part of the Seller are necessary to authorize this Agreement or to consummate the Transactions. This
Agreement and the other Transaction Documents, as applicable, have been duly and validly executed and delivered by the Seller. This Agreement
and the Transaction Documents constitute the legal, valid and binding obligation of the Seller, enforceable by Purchaser against it,
in accordance with their respective terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium and other similar
Laws and equitable principles related to or limiting creditors’ rights generally and by the availability of equitable remedies
and defenses.

 

3.4 No
Conflicts; Required Consents. No consents from a third party (including Governmental Entity6) other than those set
forth in Schedule ‎4.4 are required with respect to Seller’s execution, delivery and performance of this Agreement
and the other Transaction Documents and the consummation of the Transactions contemplated hereby and thereby. Other than as set forth
in Schedule ‎4.4, the execution, delivery and performance of this Agreement and the other Transaction Documents
by the Seller do not and will not, with or without notice or lapse of time:

 

(a) Conflict
with or violate any of the terms, conditions or provisions of its articles of association;

 

(b) conflict
with or violate (with or without the giving of notice or the lapse of time or both), or require any consent, registration, declaration,
approval, filing or notice under any Law7 applicable to the Seller or by which any property or asset of the Seller is bound
or affected;

 

 

		6	“Governmental
Entity” means any government or any agency, bureau, board, commission, court, department, official, political subdivision,
tribunal or other instrumentality of any government, whether federal, state or local (including, but not limited to, municipal, township
or county), domestic or foreign, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental
authority (to the extent that the rules, regulations or orders of such organization or authority have the force of Law).

 

		7	“Law”
means any constitutional provision, statute or other law, rule, code, regulation, ordinance, or interpretation of any Governmental Entity
and any Order all to the extent they are legally binding upon a Person.

 

    8

     

    

 

(c) result
in any breach of or constitute a default under, or give to others any right of termination, amendment, acceleration or cancellation of,
or result in the creation of any Encumbrance on any property or asset of the Seller pursuant to, any Contract8 or Permit9;
or

 

(d) violate
or conflict with any other restriction of any kind or character to which the Seller is subject; or require it to obtain any consent of,
or make or deliver any filing or notice to, any third party (including Governmental Entity).

 

3.5 Capitalization.
The Seller: (a) is the record and beneficial owner of all of the Company Shares, and (b) has good and marketable title to the Company
Shares free and clear of any Encumbrance. No rights of any kind, written or oral, were granted to acquire from the Seller any of the
Company Shares, or any other equity of the Company, except to the Purchaser as provided in this Agreement. The Seller has full power,
right and authority, and any approval required by Law to make and enter into this Agreement and to sell, assign, transfer and deliver
its Company Shares to Purchaser.

 

3.6 Legal
Proceedings. The Seller has not received notice from any third party including Governmental Entity that consummation of the Transactions
contemplated by this Agreement would constitute a violation of any Laws. There is no pending Order or Action10, or
to the Seller’s Knowledge11 threatened, against or by the Seller adversely affecting any of the Company’s
properties or assets or the consummation of the Transactions contemplated hereunder, nor does the Seller know of any basis therefor.
There is no matter as to which the Seller has received any notice, claim or assertion, or, which otherwise has been threatened or initiated,
against or by the Seller which notice, claim or assertion would affect any of the Company or any employee or agent of the Company, nor
to the Seller’s Knowledge, are there any circumstances that could reasonably be expected to give rise to any such notice, claim or assertion.

 

 

		8	“Contract”
means any legally binding, written or oral contract, agreement, arrangement, bond, commitment, undertaking, derivative instrument, franchise,
indenture, instrument, note, lease, deed, mortgage, license or other legally binding arrangement.

 

		9	“Permit”
means any license, permit, franchise, certificate of authority, registration, approval, consent or other authorization or any waiver
of the foregoing, required to be issued by any Governmental Entity.

 

		10	“Action”
means any claim, action, cause of action, demand, complaint, investigation, inquiry, audit, notice of violation, petition, lawsuit, arbitration,
proceeding, litigation, citation, summons, or subpoena, whether civil or criminal, in law or in equity, or before any arbitrator or Governmental
Entity.

 

		11	“Knowledge”
or “knowledge” with respect to a Seller mean a fact, event, circumstance or occurrence or lack or omission
thereof (an “Event”) when (a) such Event, is actually known by the Seller, or (b) such Event is reflected in
one or more documents, visual or oral expressions that are available to the Seller and it would be reasonably expected of the Seller
to review or be aware of them.

 

    9

     

    

 

3.7 Accuracy
of Certain Information. No representations, warranties and covenants by a Seller contained in this ‎Article 3 of the
Agreement, any Transaction Document (if applicable) or any certificate furnished or to be furnished by or on behalf of such Seller in
connection herewith or pursuant hereto, contains or will contain at Closing any untrue statement of a material fact or omits or will
omit to state a material fact necessary in order to make the statements contained herein or therein, in light of the circumstances in
which they are made, not misleading.

 

Article
4

REPRESENTATIONS AND WARRANTIES regarding the COMPANY

 

4.1 Except
as otherwise indicated in the Disclosure Schedule, the Company represents and warrants to Purchaser, as of the date of this Agreement
and as of the Closing and acknowledges and confirms that the Purchaser is relying upon such representations and warranties in entering
into this Agreement, as follows:

 

4.2 Organization
and Qualifications. The Company is a private company, duly formed, organized and validly existing under the Laws of the state
of Israel, is in good standing, and has all requisite power and authority to own, lease and operate its properties and to carry on its
business as now being conducted. The Company is duly qualified or licensed to conduct its business and is in good standing in each jurisdiction
where the character of the properties owned, leased or operated by the Company or the nature of its business makes such qualification
or licensing necessary. The Company has delivered to Purchaser complete and correct copies of its articles of association as amended
through (and including) the date of this Agreement. The minute books of the Company which have been provided to the Purchaser reflect
all resolutions that have been passed, enacted, consented to or adopted by the directors (or any committee thereof) or shareholders of
the Company, in the last 5 years. The corporate records of the Company have been maintained in accordance with all applicable statutory
requirements and are complete and accurate in all respects.

 

4.3 Authority;
Enforceability. The Company has the legal capacity and all necessary power and authority to execute and deliver this Agreement
and the other Transaction Documents to which it is a party, to perform its obligations hereunder and thereunder, and to consummate the
Transactions contemplated hereby and thereby. The execution and delivery of this Agreement and the other Transaction Documents and the
consummation of the Transactions has been duly and validly authorized by all requisite action including any shareholder vote, as applicable,
and no other proceedings is necessary to authorize this Agreement or to consummate the Transactions. This Agreement and the other Transaction
Documents, as applicable, have been duly and validly executed and delivered by the Company. This Agreement and the Transaction Documents
constitute the legal, valid and binding obligation of the Company enforceable by Purchaser against it in accordance with their respective
terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium and other similar Laws and equitable principles
related to or limiting creditors’ rights generally and by the availability of equitable remedies and defenses.

 

4.4 No
Conflicts; Required Consents. No consents/approvals/authorizations from, or filings with, any third party (including Governmental
Entity) (for the avoidance of doubt, in Israel or abroad) other than those set forth in Schedule ‎4.4 are required
on Company’s part with respect to the execution, delivery and performance of this Agreement and the other Transaction Documents and the
consummation of the Transactions contemplated hereby and thereby. Except as set forth in Schedule ‎4.4
the execution, delivery and performance of this Agreement and the other Transaction Documents do not and will not at Closing, with or
without notice or lapse of time:

 

(a) conflict
with or violate (with or without the giving of notice or the lapse of time or both), or require any consent, registration, declaration,
approval, filing or notice under, any Law applicable to the Company or Seller by which any property or asset of the Company is bound
or affected;

 

    10

     

    

 

(b) result
in any material breach of or constitute a default under, or give to others any right of cancellation or termination (under the respective
terms of the applicable Contract or Permit), amendment, acceleration or cancellation of, or result in the creation of any Encumbrance
on any property or asset of the Company, or result in waiver by the Company of any of its rights, pursuant to, any Contract or Permit;
or

 

(c) violate
or conflict with any other restriction of any kind or character to which the Company is subject; or require the Company to obtain any
consent of, or make or deliver any filing or notice to, a Governmental Entity.

 

4.5 Subsidiaries.
The Company has no subsidiaries/affiliates whatsoever, it does not hold any equity in any entity, whether a joint venture/partnership/subsidiary
or other.

 

4.6 Capitalization.
The authorized share capital of the Company is NIS 10,000 divided into 1,000,000 ordinary shares of NIS 0.01 par value each. The Company’s
share capital on a Fully Diluted Basis and the recorded and beneficial holder thereof are as set forth in the capitalization table attached
as Schedule ‎4.6.

 

4.7 Financial
Statements; Changes; Contingencies.

 

(a) The
Company’s audited consolidated annual financial statements for the year ended 31 December 2021 (the “Financial Statements”)
will be, prior to Closing, attached as Schedule ‎4.7(a) to the
Disclosure Schedule.

 

(b) The
Financial Statements (a) have been prepared in accordance with the U.S. generally accepted accounting principles (hereinafter the “GAAP”12)
and consistently applied throughout the period covered thereby; (b) are in accordance with the books and records of the Company, and
(c) are true, accurate and complete in all material respect and fairly present the financial condition and operating results of the Company
as of the dates, and for the periods, indicated therein.

 

(c) Reserved.

 

(d) Other
than as set forth in Schedule ‎4.7(d), the Company has no and shall have no (as of Closing) liabilities, or debts of
any nature (including capital commitments), whether accrued, absolute or contingent; Notwithstanding the aforementioned, Schedule
‎4.7(d), also details the Companies liabilities accrued on November 2022, which, as agreed between the Parties will be paid
50% by each of the Seller and Purchaser. In addition, it is agreed that Purchaser shall bear the Company’s liabilities accrued
in December 2022.

 

 

		12	“GAAP”
means generally accepted accounting principles in United States, as in effect from time to time, consistently applied.

 

    11

     

    

  

(e) Except
as set forth in Schedule ‎4.7 of the Disclosure Schedule, since
31 December 2021:

 

i. there
has not been any material adverse change in the assets, liabilities, condition (financial or otherwise) or business of the Company from
that reflected in the Financial Statements;

 

ii. there
has not been any material damage, destruction or loss13, whether or not covered by insurance, adversely affecting the assets,
properties, conditions (financial or otherwise), operating results or business of the Company, as such business is presently conducted;

 

iii. there
has been no event, occurrence, change or effect that has had, or could reasonably be expected to have, individually or in the aggregate,
a material adverse effect with respect to the Company;

 

iv. there
has not been any change in status of any lien, claim or encumbrance or payment of any obligation by the Company, and in any event any
such event that is individually or in the aggregate, adverse to the assets, properties, condition financial or otherwise), operating
results or business of the Company, as such business is presently conducted and proposed to be conducted;

 

v. there
have not been any loans made by the Company to its Employees14, officers or directors;

 

vi. The
Company has not entered into any transaction with its officers, directors, or anyone related thereto;

 

vii. The
Company has not entered into discussions or negotiations with any party with respect to any of the foregoing;

 

viii. there
has not been any sale, transfer or lease of any of the Company’s assets, except in the ordinary course of business,

 

ix. there
has not been any creation of mortgage or pledge or imposition of lien on, any of the Company’s assets (tangible or intangible),
including Company’s securities;

 

x. there
has not been any waiver by the Company of a material right or debt owed to it;

 

 

		13	“Loss”
means any judgment, cost, damage, claim, disbursement, expense, liability, loss, deficiency, Taxes, obligation, fines, including interest
or other carrying costs, penalties, reasonable costs of legal, accounting and other professional fees and expenses, but excluding indirect
damages (it is clarified that depreciation of value of the Company’s shares is not considered indirect damage).

 

		14	“Employee”
means any current employee of a Company.

 

    12

     

    

 

xi. there
has not been any material adverse change or amendment to a Material Contract or arrangement by which the Company or any of its respective
assets or properties is bound or subject;

 

xii. there
has not been any change in any compensation arrangement or agreement with any Employee of the Company there has not been any resignation
or termination of employment of any employee or director of the Company;

 

xiii. there
has not been any declaration, setting aside or payment or other distribution in respect of any of the Company’s capital stock,
or any direct or indirect redemption, purchase, or other acquisition of any of such stock by the Company;

 

xiv. there
has not been any change in the accounting principles or practices adopted by the Company; or

 

xv. there
has not been any other event or condition of any character that is reasonably likely to have a material adverse effect on the assets,
properties, condition (financial or otherwise), operating results or business of the Company, as such business is presently conducted.

 

xvi. The
Company has not adopted, amended or terminated any employee remuneration related plan, or entered into any Employee employment contract,
paid any special bonus or special remuneration to any director, officer or Employee, or increased their salaries or wage rates;

 

xvii. there
has not been any agreement or commitment by the Company to do any of the things described in any of the Sub-sections (i) to (xvi) above.

 

(f) The
books and records of the Company, including the corporate records such as minute books and stockholder records, are located on the premises
of the Company.

 

    13

     

    

 

4.8 Tax15
and Other Returns and Reports.

 

Except
as set forth in Schedule ‎4.8:

 

(a) The
Company has timely filed (taking into account extensions of time for filing, if any) all Tax Returns that any of them was required to
file, and such Tax Returns16 are true, correct and complete in all respects. All Tax Returns filed by the Company are complete,
accurate and correct in all material respects, and such Tax Returns correctly reflected the facts regarding the income, profits, gain,
credits, net operating losses, carrybacks and carryforwards (and any limitations thereupon), business, assets, operations, activities,
status and other matters of the Company and any other information required to be shown thereon.

 

(b) All
Taxes which are due and owing and have been imposed on or with respect the Company, whether or not shown on any Tax Return, have been
paid in full on a timely basis (taking into account any valid extensions), and no other Taxes relating to the Company are due and payable
by the Company with respect to any period ending prior to the date of this Agreement.

 

(c) The
Company is not the beneficiary of any extension of time within which to pay any Taxes or file any Tax Return other than extensions of
time to file Tax Returns obtained in the ordinary course of business.

 

(d) The
Company: (i) has complied in all material respects with all applicable legal requirements relating to the payment, reporting and
withholding of Taxes (including from payments to subcontractors, consultants and lenders) and the maintenance of required records with
respect thereto; (ii) has, within the time and in the manner prescribed by applicable legal requirements, withheld from employee
wages or consulting compensation and timely paid over to the proper governmental authorities (or is properly holding for such timely
payment) all amounts required to be so withheld and paid over under all applicable legal requirements, including income and employment
Taxes, National Insurance deductions and all relevant income and employment Tax withholding legal requirements; and (iii) has timely
filed all withholding and VAT Tax returns and reports, for all periods.

 

(e) There
are no liens for Taxes on the assets of the Company, other than liens for Taxes not yet due and payable.

 

(f) No
audit, enquiry or proceedings of any Tax Return of the Company is currently pending or is to the Company’s knowledge threatened. No claim
has ever been made by any Governmental Entity in a jurisdiction where the Company do not file Tax Returns that such Company is or may
be subject to taxation by that jurisdiction. The Company has not waived any statute of limitations in respect of Taxes or agreed to any
extension of time with respect to a Tax assessment or deficiency. No issue has been subject to a discussion held between the Company
and any taxing authority, or has been raised in writing by any taxing authority, in any prior examination of the Company with respect
to the seven (7) most recent tax years ending prior to the date hereof.

 

 

		15	“Tax”
means (a) any foreign, federal, state, county or local income, sales and use, excise, franchise, license, environmental, customs duties,
national insurance, social security (or similar), registration, value added, alternative or add-on minimum, real and personal property,
transfer, gross receipt, stamp, natural resources, premium, windfall profit, capital stock, capital gains, production, business and occupation,
disability, employment, employee, escheat, payroll, license, severance or withholding Tax or charge or adjustment imposed by any Governmental
Entity, whether computed on a separate or consolidated, unitary, or combined basis or in any other manner, whether disputed or not, and
including any obligation to indemnify or otherwise assume or succeed to the Tax liability of any other Person, including any interest
and penalties (civil or criminal) and inflation linkage differentials related thereto or to the nonpayment thereof, and any Loss in connection
with the determination, settlement or litigation of any Tax liability, (b) any liability for the payment of any amounts of the type described
in (a) above as a result of being a member of an affiliated, consolidated, combined, unitary or similar group (including any arrangement
for group or consortium relief or similar arrangement) for any period, and (c) any liability for the payment of any amounts of the type
described in clauses (a) or (b) above as a result of any express or implied obligation to indemnify any other Person or as a result of
any obligation under any agreement or arrangement with any other Person with respect to such amounts and including any liability for
taxes of a predecessor or transferor or otherwise by operation of law.

 

		16	“Tax
Return” means a report, return, declaration, claim for refund or other information or documents (including any related
or supporting schedules, statements or information) filed or required to be supplied to a Governmental Entity with respect to Taxes,
and including any amendment thereof.

 

    14

     

    

  

(g) Any
unpaid Taxes reflected in the Financial Statements did not exceed the reserve for Tax liability (rather than any reserve for deferred
Taxes established to reflect temporary differences between book and Tax income), and do not exceed that reserve as adjusted for the passage
of time through the Closing Date in accordance with past custom and practice.

 

(h) The
Company has complied in all material respects with all applicable Laws relating to the collection, payment withholding and reporting
of taxes and has, within the time and the manner prescribed by Law, collected, withheld from and paid over to the proper Governmental
Entities all amounts required to be so collected, withheld and paid under applicable Laws (including from payments to subcontractors,
consultants, lenders and employee wages). The Company is not liable for any arrears of wages, compensation, taxes, penalties or other
sums for failure to comply with any of the foregoing. The Company has complied in all material respects with, and its records contain
all information and documents necessary to materially comply with, all requirements of applicable Laws relating to information reporting
and other similar filing requirements.

 

(i) All
transactions with a Related Party (as such term is defined under the Israeli Code17) (or its equivalent under the local
applicable laws) involving the Company are in compliance with applicable transfer pricing laws and regulations, are at arm’s length
and are documented, in each case in accordance with applicable Law.

 

(j) The
Company does not have a permanent establishment or other taxable presence (as determined pursuant to an applicable tax treaty or applicable
foreign Law) in any country other than the country of its formation. There have been no discussions between the Company, on the one hand,
and a tax authority, on the other hand, pertaining to, and no written claim has ever been made by a tax authority in, a jurisdiction
in which the Company does not file tax returns that the Company is or may be subject to Tax in that jurisdiction nor is there a reasonable
basis for any such claim. The Company is not or has never been subject to Tax in any country other than its country of incorporation.

 

(k) The
Company is duly registered for the purposes of Israeli value added tax or its equivalent under the local applicable laws to the extent
applicable, (“VAT”) and has complied in all respects with all requirements concerning value added taxes. The
Company has never (i) made any exempt transactions (as defined in the Israel Value Added Tax Law of 1975)(or its equivalent under the
local applicable laws) and there are no circumstances by reason of which there might not be an entitlement to full credit of all VAT
chargeable or paid on inputs, supplies, and other transactions and imports made by it; (ii) failed to collect and timely remit to the
relevant tax authority all output VAT which it is required to collect and remit under any applicable Law; and (iii) refunded or deducted
any amount of value added tax that it was not so entitled to deduct or refund.

 

 

		17	“Israeli
Code” means the Israeli Income Tax Ordinance of Israel [New Version], 1961, as amended, and the rules and regulations promulgated
thereunder.

 

    15

     

    

  

(l) The
Company has not requested or received a ruling from the ITA (or the applicable local tax authority) or any Governmental Entity on behalf
of itself or any of its employees or shareholders. The Company has never participated in or ever engaged in any transaction that required
or will require special reporting in accordance with Section 131 of the Israeli Code and the Israeli Income Tax Regulations (Tax Planning
Requiring Reporting) (Temporary Provisions), 2006, regarding aggressive tax planning. The Company has not obtained an “Opinion”,
as defined in Section 131D of the Ordinance, nor has it taken a position regarding taxation classified as a “Reportable Position”,
as defined in Section 131E of the Ordinance. Same with respect to the equivalent under the local applicable laws.

 

(m) The
Company is in compliance, in all material respects, with all terms and conditions of any tax exemptions, tax holiday or other tax reduction
agreements, approvals or orders of any taxing authority. The Company has not been granted or has claimed any tax incentive, including
grants or claims of “approved enterprise”, “benefitted enterprise” or “preferred enterprise” status.
There has been no indication from any taxing authority that the consummation of the Transactions contemplated by this Agreement would
adversely affect the ability of the Company to set off for tax purposes in the future any and all losses accumulated by the Company as
of the Closing Date.

 

(n) The
Company has delivered to Purchaser correct and complete copies of (i) all Tax Returns (including amended Tax Returns), examination reports,
and statements of deficiencies assessed against or agreed to by the Company as of Year 2018 and ending on the Agreement date, (ii) any
audit report issued relating to any Taxes due from or with respect to the Company, (iii) any closing or settlement agreements entered
into by or with respect to the Company with any Governmental Entity, (iv) all material written communications to, or received by
the Company from, any Governmental Entity including Tax rulings and Tax decisions and (v) all Tax opinions and legal memoranda and
similar documents for the Company, in each case under (ii) to (iv), for the aforesaid period as of year 2018 and ending on the Agreement
date.

 

(o) The
Company has no income, profits or gains which arose, or will arise, on or before Closing which will be required for tax purposes to be
reported by the Company for a taxable period beginning after Closing.

 

4.9 Material
Contracts.

 

(a) Schedule
‎4.9 to the Disclosure Schedule contains a true and complete list of all Material Contract to which the Company is a party.
True, correct and complete copies of each Material Contract was provided by the Company to the Purchaser. Each of such contracts and
agreements is valid and is in full force and effect, and neither the Company nor, to the knowledge of the Company, any other party thereto
is in breach thereof. The performance of the Material Contracts by the Company has met and is meeting all financial covenants relating
to its terms will not result in borrowings, if any violation of or failure by the Company or Purchaser, after the Closing, to comply
with any Law. The Company has not received any notice (written/oral or otherwise) of any intention to terminate any such agreement. Furthermore,
other than as set forth in Schedule ‎4.9‎(a)
of the Disclosure Schedule, the Company is not a party to any negotiation with a view to executing any new Material Contract.
The performance of the Material Contracts will not result in any violation of or failure by the Company to comply with any Law.

 

    16

     

    

  

(b) Other
than the Material Contracts there are no Contracts necessary to enable the Company to conduct its business substantially in the manner
in which the Business is currently being conducted and in which it is currently proposed to be conducted. The Company has not waived
any of its material rights under any Material Contract. To the Company’s knowledge there are no presently existing circumstances that
are reasonably likely to occur that would reasonably be expected to adversely affect the Company’s ability to perform its obligations
under any Material Contract. There is no supplier on which the Company is dependent which could not be replaced within a reasonable period
of time without incurring material liability.

 

(c) The
term “Material Contracts” shall mean any agreements, understandings, instruments, Contracts, undertakings or
proposed transactions, to which the Company is a party or by which it is bound that may involve or relate to (i) obligations (contingent
or otherwise) of, or payments to the Company, exceeding $30,000 each, or (ii) licensing of intellectual property rights of the Company
and/or the intellectual property rights of any third party, or (iii) distribution rights, or (iv) of the Company’s products or services,
or (v) provisions restricting the development, manufacture or distribution of the Company’s products or services, or (vi) restrictions
or limitations on the Company’s right to do business or compete in any area or any field with any person18, firm or
company, or (vii) indemnification by the Company with respect to infringements of proprietary rights; or (viii) the issuance of
any securities of the Company or any rights in respect thereto or any commitment or understanding in respect of the foregoing, or (ix)
with respect to securities of the Company, including voting or consent agreements with respect to any security of the Company or the
voting by any director of the Company, or (x) loans or credits; or (xi) has an unexpired term in excess of one year, as of the Closing
Date, and other than agreements with clients listed in Schedule ‎4.9, or (xii) is for a joint venture, partnership,
cooperative arrangement or any Contract involving a sharing of profits, or (xiii) is (directly or indirectly) with a governmental entity,
or (xiv) is a Real Property19 Lease as defined below, or (xv) represents a Contract upon which the Company is materially
dependent, or (xvi (xiii) is terminable as a result of any change of control of the Company; or (xvi) is with an existing customer, or
(xvii)that is one of five customers that provided the Company with the highest revenues, or (xviii) is with a supplier, or (xix) is for
Real Property Lease, or (xx) which is otherwise material where the payments to such supplier have exceeded in US$ 10,000 the last 12
months or are supposed to exceed in next 12 months a sum of US$ 10,000 per annum.

 

(d) Except
as disclosed in Schedule ‎4.9(d), all Material Contracts are terminable by the Company at will (for no reason) by not
more than 90 days prior written notice.

 

(e) The
Company complies in all material respects with the terms of the Third Party Licenses.

 

 

		18	“Person”
means an association, a corporation, an individual, a partnership, a limited liability company, a joint stock company, a joint venture,
an unincorporated organization, a trust or any other entity or organization, including a Governmental Entity.

 

		19	“Real
Property” means real property, appurtenances thereto, rights in connection therewith, and any interest therein, including
without limitation leasehold estates.

 

    17

     

    

 

4.10 Title;
Condition and Sufficiency of Assets; Leases.

 

(a) The
Company has good, valid and marketable title to each of its tangible assets, free and clear of any Encumbrances.

 

(b) The
buildings, plants, structures, furniture, fixtures, machinery, equipment, vehicles and other items of tangible personal property of the
Company are structurally sound, are in good operating condition and repair (normal wear and tear excepted), and are adequate for the
uses to which they are being put, and none of such buildings, plants, structures, furniture, fixtures, machinery, equipment, vehicles
and other items of tangible personal property is in need of maintenance or repairs except for ordinary, routine maintenance and repairs
that are not material in nature or cost.

 

(c) The
Transactions contemplated hereunder will give Purchaser control of the Company which in turn has, directly or through another entity,
possession of, and the right to use, all the assets required for conducting the Company’s business in the same manner as presently
conducted. Other than as listed on Schedule ‎4.10‎(c) to the Company’s Knowledge20, after the Closing,
Company will be entitled to the continued possession and use of all the assets of the Company without interference. Except for the assets
of the Company as provided in the Disclosure Schedule, there are no other assets, properties or rights that are required by the Company
to conduct its business in a manner substantially consistent in all material respects with the manner in which the Company currently
conducts its business.

 

(d) the
Company does not own and never owned any real property. The lease listed on Schedule 4.10(d) (the “Real Property
Lease”) is the only interest of the Company in any real property, and the leasehold interests existing thereunder constitute
the only real property interest used by the Company in the conduct of its business and such Schedule provides an accurate and complete
list of such leases. The Real Property Lease is in effect, binding and enforceable against the Company, and to the Company’s knowledge,
each other party thereto. The Company has delivered to Purchaser accurate and complete copy of the Real Property Lease.

 

4.11 Intellectual
Property.

 

(a) Each
of the persons and entities (including without limitation the current and past officers, directors, employees and consultants of the
Company) who was, as well as those who are, involved in the development of the Company’s Owned Intellectual Property21
or otherwise participated in or contributed to the development of the Owned Intellectual Property (each a “Contributor”
and collectively the “Contributors”), has executed a proprietary information and inventions assignment and
development rights agreement in favor of the Company, which granted all right, title and interest in such Owned Intellectual Property
to the Company. None of the Contributors, nor any of their prior employers, has or had, or threatened to have, or, to Company’s
Knowledge, have a reason why he should have, any claim with respect to the Owned Intellectual Property or any rights in connection thereto,
including without limitation proprietary rights, or rights to receive any royalties or other payments or compensation.

 

 

		20	“Company’s
Knowledge” or “Company knowledge” or similar terms mean a fact, event, circumstance or occurrence
or lack or omission thereof (an “Event”) when (a) such Event, is actually known by any of the company’s
current or past officers or office holders (including directors), or (b) such Event is reflected in one or more documents, visual or
oral expressions that are available to such person listed in (a) above, and it would be reasonably expected of such person to review
or be aware of them.

 

		21	“Owned
Intellectual Property” means all Intellectual Property developed by a Contributor.

 

    18

     

    

 

None
of the Contributors has performed services for or otherwise was under any restrictions or obligations resulting from such person’s relations
with any government, army, university, medical institution, hospital, college or any educational or academic institution or research
center during the period of time in which any Owned Intellectual Property was created by him/her, nor has any such person, created or
developed any Owned Intellectual Property with any computers, equipment, labs or any other resource of such academic or similar institution,
or with any governmental grant.

 

(b) Schedule
‎4.11(b) contains a complete and accurate list and description (showing in each case the inventor(s), the owner(s), registration
and expiration date, registration or application number), of all the Owned Intellectual Property which is registered or in registration
process (“Registered IP”).

 

(c) The
Company unrestrictedly and exclusively owns all Owned Intellectual Property and possesses valid unrestricted rights and licenses to use
all of the Owned Intellectual Property and Third Party Licenses22, in accordance with the (respective) terms of such Third
Party Licenses. All Owned Intellectual Property is free and clear of any liens, Actions, Orders23, Claims24,
charges, security interest, Encumbrances, options, licenses, agreements, shared ownership interests or any other third-party rights of
any kind or nature whatsoever and any royalty or other payment or economic obligation to any other person or entity, and without any
known conflict with, or infringement of, the rights of others on account of such Owned Intellectual Property. Schedule ‎4.11(c)
contains a complete and accurate list and description (showing in each case the licensor and the Contract pursuant to which such
license was granted to the Company) of Third Party Licenses, which licenses do not include terms which limit the Company’s ability
to conduct its business as currently conducted.

 

(d) Rights
of third party(ies). To the Company’s knowledge there are no claims, of any kind relating to or in or with respect to the Owned
Intellectual Property, nor is the Company bound by or a party to any options, licenses or agreements of any kind with respect to the
patents, trademarks, service marks, trade names, copyrights, trade secrets, proprietary rights and processes of any other person or entity.

 

 

		22	“Third
Party Licenses” shall mean any third party components which are subject to Intellectual Property.

 

		23	“Order”
means any decree, injunction, judgment, order, ruling, determination, award or writ of a Governmental Entity.

 

		24	“Claim”
or “claim” means any claim, demand, suit, proceeding, arbitration, hearing or investigation.

 

    19

     

    

 

(e) Other
than the Owned Intellectual Property and Intellectual Property covered by Third Party Licenses, the Company does not utilize any other
Intellectual Property, and did not utilize any other Intellectual Property of third parties other than such that were covered by third
party’s licenses which have since expired. The Owned Intellectual Property and the Intellectual Property covered by the Third-Party
Licenses constitute all of the Intellectual Property used in or necessary for the operation of the business of the Company as currently
conducted.

 

(f) To
the knowledge of the Company, (i) no product or service marketed or sold (or proposed to be marketed or sold) by the Company nor other
business or activities conducted or performed by the Company, violates or infringes or constitutes a misappropriation of any Intellectual
Property rights of any other party; and (ii) there was no and there is no unauthorized use, infringement or misappropriation of any of
the Owned Intellectual Property by any other party.

 

“Intellectual
Property” means all patents, trademarks, service marks, trade names, trade dress, service names, corporate names, logos,
copyrights, copyrightable works, technology, works of authorship, designs and inventions trade secrets, licenses, domain names, URL’s
mask works, know-how, algorithms, computer programs and software, business models, business methods, business module, techniques, research
and development information technical data, information and other intangible assets and proprietary rights and processes (including,
without limitation, with respect to any and all of the above, any registrations and applications therefor) and any and all intellectual
and proprietary rights, that are associated with or related thereto.

 

“Company
Intellectual Property” means all Owned Intellectual Property and the Intellectual Property covered by Third Party Licenses.

 

(g) the
Company has not received any communications alleging that the Company Intellectual Property, or the conduct of its business or operations,
has violated, infringed or misappropriated any of the patents, trademarks, service marks, trade names, copyrights or trade secrets or
other proprietary rights of any other person or entity. No claim of invalidity or unenforceability of any Owned Intellectual Property
has been made by any other person and no proceedings are pending or, to the knowledge of the Company, threatened that challenge the validity,
ownership, enforceability, or use of any Owned Intellectual Property.

 

(h) To
the knowledge of the Company, none of the Company’s employees has, invented, discovered, created, conceived or developed any know-how,
inventions, discoveries, developments, concepts and ideas or other intellectual and proprietary rights which are associated with or related
to the business of the Company, in the course of his/her employment with the Company (including prior to his/her employment starting
date), which is not fully vested solely with the Company with no remaining right of such employee in or with respect thereto.

 

    20

     

    

 

(i) The
Company has taken and takes such action to maintain and protect each item of Owned Intellectual Property as customary in the industry
in which the Company operates. all the confidential information is being (and has been) continuously maintained in confidence by the
Company by taking precautions which are reasonable in order to protect and prevent its disclosure to unauthorized parties. All the Company’s
current and former employees, Consultants (as defined below), independent contractors and any other third party engaged by the Company
that are Contributors have entered into appropriate confidentiality, and with respect to those who are or were employed by the Company,
also non-compete written agreement with the Company.

 

(j) The
Company has complied in all material respects with the requirements of, and has filed on time all material documentation required in
dealing with, all Patent and Trademark Offices and any other patent registry agency in which its patent applications were filed, to the
knowledge of the Company all patents (if any) and patent applications are in effect, and, to its knowledge, there is no claim which renders
the inventions of the Company referred to in any of the Company’s patents, patent applications and related documentation (if any) invalid
in any manner.

 

(k) No
person or entity other than the Company, including any educational, academic or research institution, governmental body (including without
limitation the Israeli Innovation Authority (formerly known as the Chief Scientist) or other government-supported institution or any
multi-national, bi-national or international project or research funding program, contributed any funding, equipment, facilities or personnel
to the invention, creation or development of the Owned Intellectual Property.

 

(l) Open
Source.

 

i. Schedule
‎4.11(l) contains a true, complete, and accurate list of: (A) each item of Open Source Software that is used by the Company;
(B) the corresponding Open Source license pursuant to which the Company received such Open Source Software; (C) the URL or other source
from which the Company obtained such Open Source Software; (D) whether the Open Source Software is distributed by the Company; and (E)
whether the Open Source Software has been modified by the Company.

 

ii. The
use (including distribution even if the Company is not distributing it yet) by the Company or anyone on its behalf (such as subcontractors,
distributors, etc.) of any Open Source Software:

 

1. does
not and will not require the distribution of, disclosure of, or provision of access to, any source code of the Company in whole or in
part;

 

2. nor
limit the Company’s ability to charge for distribution, use, license or commercialization of the any Company product or service and/or
the Company Intellectual Property;

 

3. does
not and will not require that the any Company product or service and/or the Company Intellectual Property be licensed while enabling
making of derivative works;

 

4. does
not and will not grant, or purport to grant, any rights to any third party under the any Company product or service and/or the Company
Intellectual Property.

 

iii. The
Company has complied and is complying (including without limitation with inclusion of any copyright notices, disclaimers, or license
text) with the obligations set forth in the Open Source licenses under which it has received any Open Source Software.

 

    21

     

    

  

“Open
Source Software” means software/program which is generally being referred to as “open source software” or “free
software” or community source code, which generally means software that its source code is made available to see and use, or software
made available with the freedom to run it for any purpose, or freeware or shareware, including without limitation software which is licensed
under open source licenses which were certified by the Open Source Initiative (OSI), or software being identified as free software by
the Free Software Foundation (FSF), including but not limited to, any software which is licensed under the GNU General Public License
(GPL), GNU Lesser General Public License (LGPL), Affero General Public License (AGPL), Mozilla license, Eclipse license, The Artistic
License, the Sun Community Source License (SCSL), Common Development and Distribution license (CDDL), Apache License, Berkeley Software
Distribution license (BSD), MIT license, and/or similar licenses or distribution models. For the avoidance of doubt, it is clarified
that the aforesaid list of licenses does not constitute and shall not be considered as an exhausting list of Open Source Software, but
rather only examples of such.

 

iv. The
Company has not received any request from any Person to license, disclose or distribute source code for any Company product or service
and/or the Company Intellectual Property pursuant to a license governing Open Source Software.

 

(m) For
the avoidance of doubt it is hereby clarified that the disclosure by the Company of Open Source Software under Schedule 
‎4.11(l) does not derogate from any of its representations and warranties under this Section ‎4.11(l)(ii) to (iv)
(inclusive), or impair them in any way.

 

(n) Encryption.
The Company was not and is not involved in the use or development of, or engagement in, encryption technology, or other technology
whose development, commercialization or export is restricted under applicable law, and the Company’s business as currently conducted
does not require such entity to obtain a license from the Israeli Ministry of Defense or an authorized body thereof, or from the Israeli
Ministry of Economy pursuant to any legislation applicable to the Company, regulating the development, commercialization or export of
technology.

 

4.12 Data
Privacy. In connection with its collection, storage, transfer (including, without limitation, any transfer across national borders)
and/or use of any personally identifiable information from any individuals, including, without limitation, any customers, prospective
customers, employees and/or other third parties, the Company is and has been in compliance with all applicable laws in all relevant jurisdictions
and with the requirements of any Contract or codes of conduct to which the Company is a party.

 

4.13 Legal
Proceedings. No Law has been enacted, entered, issued, promulgated or enforced, and, except as set forth in Schedule ‎4.13,
there is no Action that is pending or that has to the Company’s knowledge threatened, in each case, that would prohibit or restrict the
Transactions contemplated by this Agreement. The Company has not received notice from any third party including Governmental Entity that
consummation of the Transactions contemplated by this Agreement would constitute a violation of any Laws. There is no pending Order or
Action or Claim, nor has any been threatened, against or by the Company affecting the Company’s properties or assets including
Owned Intellectual Property or the consummation of the Transactions contemplated hereunder, nor to the Company’s knowledge is there any
basis therefor. There is no other matter as to which any of the Company has received any claim, assertion, or threat, against or by the
Company affecting the Company or to the knowledge of the Company any Employee (in their capacity as such), nor does the Company have
knowledge that there are currently any circumstances that would reasonably be expected to give rise to any such claim, assertion or threat.

 

    22

     

    

 

4.14 Insurance.
The Company is, and at all times continually during the past three (3) years has been, insured with reputable insurers against such losses
and risks in such amounts as are customarily insured against by companies in similar lines of business, and all such insurance policies
required to be maintained by the Company are in full force and effect and all premiums due thereon have been paid. The Company has complied
in all material respects with the terms and provisions of such policies. Schedule ‎4.14 sets forth a true and complete
list of all insurance policies of the Company. The Company is not in breach or default under any such policy or has received any notice
of cancellation or non-renewal of, or material premium increase with respect to, any policy. The Company has timely filed claims with
its insurers with respect to all matters and occurrences for which it believes it has coverage. There are no outstanding requirements
by any insurance company that issued a policy with respect to the Company which have not yet been met. Other than as set forth in Schedule
‎4.14, during the past three (3) years, there have not been any claims or to the Company’s Knowledge any circumstances that
would give rise to a claim under any of the insurance policies

 

4.15 Compliance
with Law; Permits.

 

(a) The
Company has conducted its business in accordance with applicable Laws in all material respects. The use and operation of the assets of
the Company are in compliance in all material respects with all applicable Laws, including building codes, zoning, subdivision, and land
use Laws, and other local, state and federal Laws, and there are no material violations of any such Laws.

 

(b) Without
derogating from the generality of the forgoing: (i) in its manufacturing, marketing, promotion, sale, distribution and export of its
products and services, the Company complies with all applicable laws and regulations pertaining to such activities, including without
limitation those relating to the Israeli Defense Export Controls Agency (hereafter: DECA), to the extent these are applicable to the
Company, and (ii) the Company’s share capital issued and outstanding has been offered or sold in such a manner as to make the issuance
and sale of such shares exempted from such prospectus delivery requirements, and all such shares of share capital have been offered and
sold in compliance with all applicable securities laws.

 

(c) The
Company and each of its employees and contractors holds all Permits that are required by any Governmental Entity to permit the conduct
of its business as now conducted, as listed in Schedule  ‎4.15 and all such Permits are valid and in
full force and effect and will remain in full force and effect upon consummation of the Closing, and all applications or filings for
renewals have been timely made for such Permits. No suspension, cancellation or termination of any of the foregoing Permits is pending
or has to the Company’s Knowledge been threatened.

 

    23

     

    

 

4.16 Employment
Matters.

 

(a) Schedule
‎4.16(a) is an accurate and complete list of the names of the Company’s Employees, their respective titles or positions,
their annual compensation (broken out by base salary, bonuses, deferred compensation and commission arrangements), accrued and unused
paid vacation and paid sick leave, years of service, and estimated entitlements to receive supplementary retirement benefits or allowances
(whether pursuant to a contractual obligation or otherwise), and their respective prior written notice for termination period. Schedule
‎4.16(a) also provides general information as to the benefits such Employees receive from the Company including, if applicable,
managers insurance, pension funds, study funds (“Keren Hishtalmot”), use of automobiles or any other benefits. No
Employee has been granted the right to continued employment by the Company or to any material compensation following end of employment
relationship with the Company (such as, for example only, garden leave). No Employee has given notice of termination or to the Company’s
knowledge intends to terminate his or her employment with the Company, nor has the Company given notice of termination to an Employee,
and the Company has no present intention to terminate the employment of any Employee. Schedule ‎4.16(a) also provides
details of any pending (“open”) job offering made by the Company.

 

(b) Without
limiting the generality of any other representation or warranty contained in this Section ‎4.16 and except as set forth in
Schedule ‎4.16: (i) the employment of each Employee is terminable by the Company upon no more than 30 days prior written
notice under the termination notice provisions included in the applicable employment Contract with such Employee or applicable Law; (ii)
all obligations of the Company to provide the entire statutory severance pay to all employees are in accordance with Section 14 of the
Israeli Severance Pay Law (5723-1963) (the “Severance Pay Law”) and the provisions of the General Approval
Regarding the Payment by Employers to Pension Funds and Insurance Funds, in Lieu of Severance Payments pursuant to Section 14 of the
Severance Pay Law – 1963 and are fully funded, and all Employees have been subject to the provisions of Section 14 of the
Severance Pay Law with respect to their entire salary, as defined under the Severance Pay Law from the date of commencement of their
employment with the Company, and the Company has been in full compliance with the requirements for a Section 14 Arrangement with respect
to severance pay with respect to 100% of such salary for which severance pay is due under the Severance Pay Law; (iii) no Employee’s
employment by the Company requires any special license, permit or other authorization by any Governmental Entity; (iv) there are no unwritten
policies, practices or customs of the Company that entitle any Employee to benefits in addition to what such Employee is entitled to
by applicable Law or under the terms of such Employee’s employment Contract (including unwritten customs or practices concerning
bonuses, the payment of statutory severance pay when it is not required under applicable Law, etc.); (v) all amounts that the Company
is legally or contractually required either: (A) to deduct from employees’ salaries or to transfer to such employees’ pension
or provident, life insurance, incapacity insurance, study fund (Keren Hishtalmut) or other similar funds or (B) to withhold from
employees’ salaries and benefits and to pay to any Israeli Governmental Entity as required by applicable tax Law, have, in each
case, been duly deducted, transferred, withheld and paid, and the Company does not have any outstanding obligation to make any such deduction,
transfer, withholding or payment. Except as set forth in Schedule ‎4.16(b)(i) all current Consultants are engaged by
the Company pursuant to a written Contract (including agreement by email). The Company has furnished to Purchaser (x) copies of all Contracts
with human resource contractors, or with current Consultants and (y) copies of manuals and written policies relating to the employment
of employees or termination thereof. There are no sums owing to any current or former Employee or Consultant of the Company.

 

    24

     

    

  

(c) No
current or former Consultant of the Company (“Consultant” means any service provider, consultant, independent
contractor, freelancer, independent contractor, advisor, director or other Person who has provided or provides services to the Company,
other than an Employee) could reasonably be deemed to be a misclassified employee. The Company has never had any temporary or outsourced
(such as manpowered) employees who were not treated and accounted for in all respects as the law requires with respect to such employees,
as applicable. Without derogating from the above, except as provided in Schedule ‎4.16(c), the Company has not engaged
any current or former Consultant in a scope of hours constituting the major part of such Consultant’s labor week or in a manner
that such Consultant performs services only for the Company, but rather to additional service consumers as well. Schedule ‎4.16(c)
is an accurate and complete list of the names of each current Consultant performing services for the Company the date as of which
such Consultant was originally engaged by the Company, a description of such Consultant’s duties and responsibilities, the annual
aggregate amount of the compensation (including all fees, payments, commissions or benefits of any type) received by such Consultant
and any Permit that is held by such Consultant and that relates to the Company. No Consultant has been granted the right to continued
engagement by the Company or to any material compensation following end of engagement with the Company.

 

(d) 
all pending or threatened claims regarding labor law issues are set forth in full in Schedule ‎4.16(d).

 

(e) Except
as set forth in Schedule ‎4.16(e), the Company has complied with all Laws related to the employment of its employees
or the engagement of Consultants, including provisions related to wages, hours, overtime exemption classification, compensation for overtime
hours, independent contractor classification, leaves of absence, equal opportunity, privacy right, retaliation, immigration, wrongful
discharge, occupational health and safety, workers’ compensation, severance, employee handbooks or manuals (if any and to the extent
legally binding), collective bargaining agreements (if any) and the payment of social security and other Taxes, including without limitation,
as required according to the following: The Prior Notice to the Employee Law, 2002, The Notice to Employee and Job Candidate (Terms of
Employment and Candidate Screening and Selection) Law, 2002, the Prevention of Sexual Harassment Law, 1998, the Hours of Work and Rest
Law, 1951, the Annual Leave Law, 1951, The Salary Protection Law, 1958, The Employment by Human Resource Contractors Law, 1996, and the
Law for Increased Enforcement of Labor Laws, 2011 and all extension orders applicable to the Company and/or any employees. The Company
is not liable for any Claim or Action under any Laws related to employment and attributable to an event occurring or a state of facts
existing prior to the date thereof.

 

4.17 Anti-Corruption,
Anti-Money Laundering, and Trade Compliance. Neither the Company, nor any of its directors, officers, employees, or agents, in
their capacity as directors, officers, employees or agents of the Company has or is violated/violating any Anti-Corruption Law25.

 

 

		25	“Anti-Corruption
Law” means all applicable national and international anti-bribery laws and conventions, inter alia, the United Nations
Convention Against Corruption, the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions,
Israeli Penal Law 5737-1977, § 290-297, the Indian Prevention of Corruption Act, 1988, No. 49, Acts of Parliament (Sept. 9, 1988),
U.K. Bribery Act, UK ST 2010 c. 23, the U.S. Foreign Corrupt Practices Act, 15 U.S.C.A. § 78dd-1 (1977), the U.S. Travel Act, the
U.S. domestic bribery statute contained in 18 U.S. Code § 201 the Israeli Prohibition on Money Laundering Law, 2000, and all other
applicable local, municipal, state, federal, or national Laws in Israel, India or the United States or any other applicable country regarding
corruption, bribery, kickbacks, revolving doors, ethical business conduct, fraud, racketeering, political contributions, gifts, hospitalities,
expense reimbursements, representative relationships, commissions, lobbying, books and records, and financial controls.

 

    25

     

    

  

4.18 Certain
Interests; Indemnification Liabilities. To the Company’s knowledge no director or officer or employee of the Company, nor any
of their respective Affiliates26, has an interest of any nature whatsoever in any Person, including corporation,
joint venture, partnership or other entity, which is involved in a Competitive Business27.

 

4.19 No
Brokers or Finders. No agent, broker, finder, or investment or commercial banker, or other Person or firm engaged by or acting on
behalf of the Company in connection with the negotiation, execution or performance of this Agreement or the Transactions contemplated
by this Agreement, is or will be entitled to any brokerage or finder’s or similar fee or other commission as a result of this Agreement
or such Transactions, except as set forth in Schedule ‎4.19.

 

4.20 Related
Party Transactions. None of: (i) the Company’s shareholders that are Employees, or officers, (ii) directors or (iii) to
the Company’s knowledge any of their immediate family members or affiliates (collectively “Interested Party(ies)”),
was, nor presently is, a party to any transaction or engagement with the Company. To the Company’s knowledge, no Interested Party: (i)
has any direct or indirect interest in any asset used by the Company; (ii) is indebted to the Company nor is the Company indebted (or
committed to make loans or guarantee credit) to any of them; (iii) has entered into, or has had any direct or indirect financial interest
in, any agreement, transaction or business dealing (including provision of services) with or involving the Company; and (iv) has any
direct or indirect ownership interest in any entity (whether corporate or not) with which the Company is affiliated or with which the
Company has a business relationship.

 

4.20(a)
Customers and Suppliers.

  

(a) Schedule
‎4.20(a)(i) lists the top five (5) existing customers of the Company (from the perspective of income during the 2021 calendar
year), as well as all suppliers upon which the Company is dependent. No customer listed on Schedule ‎4.20(a)(i) has
notified the Company until the signature date of this Agreement, that (i) it intends to terminate its relationship with the Company whether
or not as a result of the Transactions contemplated hereunder, or (ii) it will or is reasonably likely to fail to perform, its obligations
under any Contract with the Company in any manner that is adverse to the Company. Schedule ‎4.20(a)(ii) lists the 20
biggest suppliers of the Company (from the perspective of payments paid to them during the last 12 months). No supplier listed on Schedule
‎4.20(a)(ii) has notified the Company, that (i) it intends to terminate its relationship with the Company, or (ii) it will
or is reasonably likely to fail to perform, its obligations under any Contract with the Company in any manner that is adverse to the
Company, and in each case the Company does not have reasons to believe there will be such termination or failure to perform.

 

 

		26	“Affiliate”
of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is
under common control with, such Person. The term “control” (including the terms “controlled by” and “under
common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management
and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

 

		27	“Competitive
Business” means Quad rotor, truck-mounted, heavy payload tethered drone.

 

    26

     

    

 

(b) The
Company does not provide services based on verbal arrangements or email communications.

 

(c) Except
as set forth in Schedule ‎4.20(c), there are no outstanding liabilities or pending disputes with customers and suppliers
relating to services provided up to the date hereof and such which will be provided up until the Closing Date.

 

4.21 Government
Grants. The Company has not applied for or received any grants, incentives, exemptions and subsidies from the Government of the
State of Israel or any Governmental Entity thereof, or from any non-Israeli Governmental Entity, including grants from the Israeli National
Authority for Technological Innovation, of the Israeli Ministry of Economy and Industry (collectively, “Government Grants”).

 

4.22 Accuracy
of Certain Information. No statement (including the representations, warranties and covenants) by the Company contained in this Agreement,
the Disclosure Schedule, the exhibits and schedules attached hereto, or any Transaction Document or any statement or certificate furnished
or to be furnished by or on behalf of the Company or its representatives in connection herewith or pursuant hereto, contains or will
contain at Closing any untrue statement of a material fact or omits or will omit at Closing to state a material fact necessary in order
to make the statements contained herein or therein, in light of the circumstances in which they are made, not misleading. There is no
fact (other than matters of a general economic or political nature which do not affect the Company uniquely) known to the Company or
Seller that has not been disclosed herein to Purchasers that might reasonably be expected to have or result in a material adverse effect
or that would reasonably be material in Purchasers’ assessment of the Transaction.

 

Article
5

REPRESENTATIONS AND WARRANTIES OF PURCHASER

 

Purchaser
represents and warrants as of the date of this Agreement and as of the Closing, and acknowledges and confirms that the Company and Seller
are relying upon such representations and warranties in entering into this Agreement, as follows:

 

5.1 Organization
and Related Matters. Purchaser is a corporation duly organized, validly existing and in good standing under the Laws of the state
of Israel. Purchaser has the necessary power and authority to execute, deliver and perform this Agreement and the other Transaction Documents
to which it is a party, to perform its obligations hereunder and thereunder and to consummate the Transactions contemplated by this Agreement
and such Transaction Documents.

 

5.2 Authorization.
The execution, delivery and performance of this Agreement and any other Transaction Document by Purchaser have been duly and validly
authorized by the Board of Directors of Purchaser and by all other necessary corporate action on the part of Purchaser, and no other
action on the part of the Purchaser is necessary with respect thereto. This Agreement and the other Transaction Documents to which it
is a party constitute the legal, valid and binding obligation of Purchaser, enforceable against Purchaser in accordance with its terms.

 

    27

     

    

 

5.3 No
Conflicts; Required Consents. No consents/approvals/authorizations from a third party, including any Governmental Entity are
required with respect to the Purchaser’s execution, delivery and performance of this Agreement and the other Transaction Documents
to which it is a party and the consummation of the Transactions contemplated hereby and thereby. The execution, delivery and performance
of this Agreement and the other Transaction Documents by Purchaser do not and will not conflict with or violate the provisions of, or
constitute a breach or default whether upon lapse of time and/or the occurrence of any act or event or otherwise, or require any consent,
registration, declaration, approval, filing or notice under (a) the charter documents or bylaws of Purchaser, (b) any Law to which Purchaser
or its assets or properties are subject, or (c) any agreement entered by Purchaser with any third party to which Purchaser is a party.
The execution, delivery and performance of this Agreement and the other Transaction Documents by Purchaser do not violate or conflict
with any other material restriction of any kind or character to which the Purchaser is subject.

 

5.4 No
Brokers or Finders. No agent, broker, finder or investment or commercial banker, or other Person or firm engaged by or acting
on behalf of Purchaser (other than legal, accounting, IP and alike advisors) in connection with the negotiation, execution or performance
of this Agreement or the Transactions contemplated by this Agreement, is or will be entitled to any broker’s or finder’s
or similar fees or other commissions as a result of this Agreement or such Transactions.

 

Article
6

COVENANTS

 

6.1 Non-Competition;
Non-Solicitation.

 

(a) The
Seller acknowledges that, immediately following the Closing, Purchaser shall be the sole shareholder of the Company and thus own and
be entitled to the exclusive use and enjoyment of the Company as a going concern, and to protect and preserve the same to the maximum
extent permitted by Law.

 

(b) the
Seller also severally acknowledges that his contribution as a shareholder of the Company have been uniquely valuable and involve proprietary
information, including trade secrets that would be unfair to make available to any competitor of the Company. For these reasons and as
an inducement to Purchaser to enter into this Agreement, the Seller undertakes that, from and subject to the Closing and ending two (2)
years after Closing, the Seller shall not, directly or indirectly (including by licensing or through any other Person directly or indirectly
controlling, controlled by or under common control with the Seller):

 

1. engage,
in any territory in the world, in a Competitive Business, including, without limitation, through any activity of research, development,
manufacturing, marketing, sale, distribution, servicing, licensing, sublicensing or other form of commercialization.

 

    28

     

    

  

2. acquire,
own, invest in, manage, operate, control or participate in any manner in the ownership, financing, management, operation or control of
any business that engages or intends to engage in the Competitive Business except that the limitation set forth in this Section ‎6.1(b)‎2
shall not apply with respect to the passive ownership of less than 1% of the shares of any public company

 

3. contact
any customer or supplier of the Company for the purpose of soliciting orders or establishing relationships for any business enterprise
that engages in a Competitive Business or otherwise utilize its knowledge of the business of the Company or its relationships with customers,
suppliers or others to engage or facilitate others to engage in any Competitive Business,

 

4. cause,
induce or encourage any customer, supplier, distributor, representative, or other business partner of the Company to terminate or modify
such relationship,

 

5. solicit
or attempt to induce any supplier, distributor, representative, or other business partner of the Company into any Competitive Businesses

 

6. solicit,
or attempt to solicit any person who is at such time, an: (i) employee, or (ii) consultant/service provider who works primarily for the
Company, to leave their employment or engagement with the Company.

 

7. recruit,
hire, or retain or attempt to do so (whether as an employee, consultant, agent, independent contractor or otherwise) any person who is
at such time, or was during the 6 months preceding such time, an: (i) employee, or (ii) Consultant who works exclusively for the Company,
or

 

8. enter
into any agreement or understanding to do any of the foregoing

 

Notwithstanding
anything to the contrary herein, (i) it is acknowledged that Seller and/or Seller’s Affiliate owns Drone (Lighter than Air Systems
/ Drone Aviation) and any activity related to said business shall not be deemed a breach of this Section ‎6.1, and (ii) it
is acknowledged that Seller and/or Seller’s Affiliate owns a Sensor business (Rvision Inc.), which will be subject to the provisions
of this Section ‎6.1.

 

(c) The
Parties hereto hereby acknowledge and agree that any remedy at Law for any breach of the provisions of this Section ‎6.1 may
be inadequate, and the Seller hereby consents, without derogating from any other right or remedy available, to the granting by any court
of an injunction or other equitable relief, without the necessity of actual monetary loss being proved or any bond or similar security
being posted, in order that the breach or threatened breach of such provisions may be effectively restrained.

 

(d) The
provisions of this Section ‎6.1 do not intend to limit or derogate from any right or remedy otherwise available to the Purchaser
by Law.

 

    29

     

    

 

(e) 
The Parties agree that the covenants of the Seller not to compete contained in this Section ‎6.1, may be assigned by Purchaser,
without the prior written consent of the Seller, to any of its Affiliates or to any other Person to which the Purchaser may transfer
the Company or its business, or to any other Person with or into which the Purchaser may hereafter merge or consolidate or to which the
Purchaser may transfer all or substantially all of its business and assets. It is the Parties’ intention that these covenants the
Seller under this Section ‎6.1 as well as those under Section ‎6.2 shall inure to the benefit of any Person that
may succeed the Company, its business and its assets or any part thereof with the same force and effect as if these covenants were made
directly with such successor.

 

6.2 Confidentiality.

 

(a) The
Seller agrees not to directly or indirectly use or disclose any Confidential Information (as hereinafter defined) that the Seller may
have or acquired. The term “Confidential Information” as used in this Agreement means any information, data and know-how
relating to the Company, its business, its assets, or its clients and referral sources that is developed by or disclosed to the Seller
or known to the Seller as a result of its relationship with the Company, including, without limitation, the following information:

 

(i) Information
related to the Company Intellectual Property;

 

(ii) financial
information, such as the Company’s earnings, assets, debts, cost-price information, fee structures, or other financial data;

 

(iii) supply
and service information, such as information concerning the goods and services (including software licenses) utilized or purchased for
the Company, the names or addresses of suppliers and vendors, terms of supply or service Contracts (including software licensing Contracts),
terms of supply, or of particular transactions, or related information about potential suppliers or vendors, to the extent that such
information is not generally available to the public, and to the extent that the combination of suppliers or vendors or use of a particular
supplier or vendor, though generally known or available, yields advantages to Purchaser and the details of which are not generally known;

 

(iv) marketing
information, such as details about ongoing or proposed marketing programs or agreements relating to the Company, marketing forecasts
or results of marketing efforts or information about impending transactions;

 

(v) personnel
information, such as employees’ personal or medical histories, compensation or other terms of employment, actual or proposed promotions,
hirings, resignations, disciplinary actions, terminations or reasons therefor, training methods, performance, or other employee information;
and

 

(vi) customer
information, such as any lists or compilation of past, existing or prospective customers, customer proposals or agreements between customers
and the Company, status of customer accounts or credit, or related information about actual or prospective customer.

 

Notwithstanding
the foregoing, the term “Confidential Information” does not include information that has become generally available
to the public other than as a result of its disclosure by the Seller. Any combination of information shall not be deemed within the foregoing
exception merely because individual features are generally available to the public if the combination itself is not generally available
to the public.

 

(b) The
covenants contained in this Section ‎6.2 shall survive the Closing for as long as the Confidential Information remains a trade
secret of the Company.

 

    30

     

    

  

(c) In
the event that Seller is requested or required (by oral questions, interrogatories, requests for information or documents, subpoena,
civil investigative demand or other process) to disclose any Confidential Information relating to the Company, it agrees to provide the
Purchaser (to the extent not prohibited by law) with prompt notice of any such request or requirement so that the Purchaser may seek
an appropriate protective order or waive compliance with the provisions of this Agreement. If, failing the entry of a protective order
or receipt of a waiver hereunder, the Seller is compelled to disclose Confidential Information, it may only disclose that portion of
the Confidential Information which its legal counsel advises that it is compelled or required to disclose, provided that it notifies
the Purchaser (to the extent not prohibited by law) not later than the time of such disclosure of the nature and extent of such disclosure.
In any event, the Seller agrees not to oppose any action by or on the behalf of, and to cooperate with, the Purchaser to obtain an appropriate
protective order or other reliable assurance that confidential treatment will be accorded the Confidential Information.

 

(d) Notwithstanding
anything to the contrary in this Agreement, it is acknowledged that the Seller is wholly owned by a U.S. publicly traded company, and
that any public announcements or statements required under any SEC regulation, or regulation of any applicable stock exchange, shall
not be subject to the procedures in Section ‎6.2(c) above, and may be made without prior notice to the Purchaser, provided
however, that the Seller (or Seller’s sole shareholder) shall coordinate with the Purchaser, prior to Closing, the wording of the
initial public announcement of these Transactions.

 

6.3 Further
Assurances. Upon the terms and subject to the conditions set forth in this Agreement, at any time and from time to time, each
of the Parties hereto shall take such actions and execute and deliver such documents as may be reasonably necessary to effectuate the
purposes of this Agreement (and any agreements ancillary hereto) at the earliest practicable time. Furthermore, the Parties will cooperate
and seek to obtain all consents necessary for consummation of the Transaction before the Closing, and if any acquisition of any material
right or agreement the benefit of which is to be acquired by Purchaser pursuant to this Agreement shall require the consent of any other
party and such consent has not been obtained prior to the Closing, the Seller will reasonably cooperate with Purchaser, in any reasonable
arrangement requested by Purchaser designed to obtain such consent. The Seller may not change, or offer to change, any terms thereof
in order to obtain such a consent without Purchaser’s express written permission. Nothing in this Section ‎6.3 constitutes
a waiver by Purchaser of its right to have received on or prior to the Closing an effective consent in respect of the affected asset
of the Company.

 

6.4 Conduct
of Business Prior to the Closing. From the date hereof until the Closing, the Company shall conduct its business in the ordinary
course of business consistent with past practice but shall not enter into, or renew any Contract with customers/clients without obtaining
Purchaser’s prior written approval. Without limiting the generality of the foregoing, except as expressly contemplated by this
Agreement, from the date hereof until the Closing, without the prior written consent of Purchaser, the Company and the Seller shall procure
that the Company shall not: (i) sell or dispose of any of its assets or properties; (ii) amend, terminate or assign, or waive any material
rights under, any Material Contract; (iii) grant any increase in the compensation or benefits of any Employee, officer or director of
the Company; (iv) solicit any Employees who, as of the date of this Agreement, is employed by the Company to become employed by the Seller;
(v) alter the manner in which they have regularly and customarily maintained their books of account and records or change any method
of financial accounting or accounting practice or policy used by them, other than as required by GAAP, (vi) distribute any dividends,
and (vii) change their collection practices.

 

    31

     

    

  

Article
7

CONDITIONS PRECEDENT TO OBLIGATIONS OF PURCHASER - CLOSING

 

The
obligations of Purchaser under this Agreement shall, at the option of Purchaser, be subject to the satisfaction or waiver, on or prior
to the Closing, of the following conditions:

 

7.1 The
representations and warranties of the Seller in Articles 3 and the Company in Article 4 of this Agreement shall be in all material
respects true, correct and complete on the Closing date as if made on the Closing date.

 

7.2 The
Company shall have obtained any and all consents, permits, waivers, acknowledgements, approvals and consents necessary for consummation
of the transactions contemplated by this Agreement as set forth in Schedule 2.2(d).

 

7.3 All
covenants, agreements, and conditions contained in this Agreement to be performed or complied with by the Company prior to or at the
Closing, including under Section ‎2.2 shall have been performed or complied with by the Company prior to or at the Closing

 

7.4 There
shall have been no breach by the Company, in the performance of any of its covenants and agreements herein.

 

7.5 All
of the documents to be delivered hereunder by the Company shall be in a form and substance reasonably satisfactory to the Purchaser and
its counsel, and shall have been delivered to the Purchaser.

 

7.6 All
corporate proceedings on the part of the Company as specified in this Agreement required for the consummation of the transactions contemplated
by this Agreement and the Transaction Documents shall have been completed.

 

7.7 Between
the date hereof and the Closing Date, there shall have been no Material Adverse Effect with respect to the Company.

 

7.8 There
shall not be on the date of the Closing any judgment or order of a court of competent jurisdiction or any ruling, regulation or order
of any authority which would prohibit or have the effect of preventing consummation of the transactions contemplated by this Agreement.

 

7.9 Duly
executed copies of the Employment Agreements in substantially the form of Exhibit D, (collectively, the “Purchaser
Employment Package”), to become effective upon the Closing, signed by each of the Key Employees on the one hand, and the
Company, on the other hand;

 

    32

     

    

 

7.10 The
Seller’s representation under Section 4.7(d) above shall have been true and accurate, and all such debts were covered (paid)
and fully released and discharged (including confirmation to the satisfaction of Purchaser, evidencing the removal of the claim pending
against the Company in labor court) using the Escrow Amounts in accordance with the terms of the Escrow Agreement, between the Pre-Closing
to Closing.

 

(a) Nevertheless
and without derogating from Purchaser’s available remedies for breach of representations and warranties in accordance with this
Agreement, if it will turn out that the Company has further financial debt (defined as financial obligation not paid when due) beyond
its debts as represented by Seller under Section ‎4.7(d) (in this Agreement, “Surplus Debt”), the Purchaser
shall have the right (but not the obligation), with seven (7) days prior notice to the Seller to close while using the Purchase Price
for paying and discharging such Surplus Debt, in accordance with the terms of the Payment Agent Agreement (so only the amount left out
of the Purchase Price – which was not used for covering the Surplus Debt – will be used for payment to the Seller, notwithstanding
anything herein to the contrary).

 

The
mechanism described above regarding Surplus Debt shall apply, with the necessary changes (mainly being the fact that it’s a post-Closing
mechanism that does not refer to the question of whether to close the transaction or not, but rather only to the ability to set-off amounts),
to Surplus Debt that may be discovered after Closing, and the right of the Purchaser to set it off, following prior written notice to
the Seller, from the 600,000 Payment. It is agreed, that except as detailed in Section ‎9.4 of this Agreement, no setoff is
permitted, to any Loss which is not a Surplus Debt.

 

ARTICLE
7A

CONDITIONS PRECEDENT TO OBLIGATIONS OF PURCHASER – PRE CLOSING

 

The
obligations of Purchaser for consummating the Pre-Closing under this Agreement shall, at the option of Purchaser, be subject to the satisfaction
or waiver, on or prior to the Pre Closing, of the following conditions:

 

 7A.1 The conditions set forth in Sections ‎7.1, ‎7.3, ‎7.7, ‎7.8, shall be fulfilled, with respect to the Pre-Closing, as if it was the Closing (mutatis mutandis);

 

 7A.2 The terms of Sections ‎7.2, ‎7.4, ‎7.5, ‎7.6, ‎7.9 shall be fulfilled.

 

Article
8

CONDITIONS PRECEDENT TO OBLIGATIONS OF Seller

 

The
obligations of the Seller under this Agreement shall, at the option of the Seller, be subject to the satisfaction, on or prior to the
Closing Date, of the following condition: (i) the representations and warranties of the Purchaser set forth in Article 5 of this Agreement
shall be true, correct and complete in all material respects on the Closing date as if made on the Closing date; and (ii) Purchaser shall
have performed in all material respects all covenants and obligations required to be performed by it under this Agreement at or prior
to the Closing Date;

 

    33

     

    

 

Article
9

INDEMNIFICATION

 

9.1 Survival.

 

(a) The
representations and warranties contained in or made pursuant to this Agreement shall survive both the Pre-Closing and the Closing and
shall remain in full force and effect until the date that is 12 months after the Closing Date except:

 

(i) the
representations and warranties contained in Section ‎4.11 (Intellectual Property) and ‎4.19 (No Brokers or Finders),
shall survive the Closing and shall remain in full force and effect until the date that is 36 months after the Closing Date;

 

(ii) the
representations and warranties contained in Sections‎3.2 and‎4.2 (Organization and Qualifications), Sections ‎3.3 and
‎4.3 (Authority; Enforceability), Sections ‎3.4 and ‎4.4 (No Conflicts; Required Consents), Sections ‎3.5
and ‎4.6 (Capitalization), Section ‎4.17 (Anti-Corruption, Anti-Money Laundering, and Trade Compliance), and Section
‎4.21 (Government Grants) shall survive the Closing and shall remain in full force and effect until the earlier of the seventh
(7th) anniversary of the Closing Date or the sixtieth (60th) day following the expiration of the applicable statutes
of limitations (the representations and warranties set forth in Section ‎9.1(a)(i) herein, the “Special Representations”,
the representations and warranties set forth in Section ‎9.1(a)(ii) above, the “Fundamental Representations”,
and all other representations and warranties, the “Non-Fundamental Representations”).

 

(b) if
a written claim or notice is given to Sellers under this Article 9 (Indemnification) (a “Claims Notice”) with
respect to any of the representation or warranty prior to the applicable expiration date, such representation or warranty shall continue
until the applicable claim is finally resolved.

 

(c) All
covenants and agreements set forth in this Agreement or any of the Transaction Documents shall survive the Closing, until the expiration
of the applicable statute of limitations, except as otherwise provided herein or therein. No claims may be brought by or on behalf of
the Purchaser with respect to any indemnifiable matter after the applicable expiration date for such claims as stated hereinabove. Notwithstanding
anything to the contrary herein, there shall be no limit to the time period for making a claim against Seller for fraud or intentional
misrepresentation or willful misconduct committed by Seller, or the Company, or of which the Company or the Seller had actual knowledge
prior to the Closing.

 

9.2 Indemnification
Obligations of Seller. Subject to the terms and conditions of this ‎Article 9,
from and after the Closing, the Seller shall indemnify, defend and hold harmless Purchaser, and its directors, officers, employees, managers,
Affiliates, agents and representatives (each an “Indemnified Party”
and collectively, the “Indemnified Parties”) from and against any
and all Losses incurred or sustained by, or imposed upon, any Indemnified Party resulting or arising from any inaccuracy in or breach
of any of the representations or warranties made by the Seller or the Company pursuant to ‎Article
3 or ‎Article 4.

 

In
the event of any third party claim which is the basis of a Claims Notice, Purchaser shall timely notify the Seller, provide Seller copies
of all pleadings, notices and communications with respect to such claim (provided, however, that failure to timely notify or provide
all such information \ documents shall not release the Seller from its indemnification obligations hereunder, except to the extent Seller
was adversely affected by such failure), and shall have the right in its sole discretion to conduct the defense of and to settle such
third party claim; provided, however, that Purchaser shall not be entitled, without the prior written consent of the Seller, admit any
liability, permit a default or consent to entry of any judgment with respect to, or settle, compromise, or offer to settle or compromise,
any third party claim, without the prior written consent of the Seller, which shall not be unreasonably withheld.

 

    34

     

    

 

Purchaser
will use all reasonable efforts to resolve the EMT Matter (as defined in Schedule ‎4.9(a)
of the Disclosure Schedule) without repayment to EMT. In the event that, notwithstanding such efforts being exercised, EMT brings
a claim against the Company, the Company and the Purchaser shall timely notify the Seller, and shall have the right, with seven (7) Business
days prior notice to the Seller, to conduct the defense of and/or to settle such claim. Within said seven (7) Business days, Seller may
approve to settle with EMT, and if so approved the Company shall so settle. If the Company will be required to pay to EMT, whether in
settlement or upon court order, such amount (including reasonable legal expenses) will be paid out of amount placed in escrow pursuant
to Section ‎9.4.

 

9.3 Certain
Limitations. Notwithstanding any provision in this Article 9 to the contrary, the obligations
of the Seller under this Article 9 will be limited as follows:

 

(a) Baskets.
The Seller shall have no liability under Section ‎9.2 unless the total cumulative amount of all Losses arising from one or
more individual breach of any of the representations or warranties exceeds USD 60,000 (“Threshold”)
in which case Purchaser may recover all such Losses from the first Dollar; provided that the provisions of this Section ‎0‎(a)
shall not apply with respect to any breach of the Fundamental Representations.

 

(b) Caps.
The Seller’s aggregate liability towards all Indemnified Parties for breach of any of the representations
or warranties:

 

(i) under
Section ‎9.2 with respect to Non-Fundamental Representations, will not exceed an amount equal to 20% of the Purchase Price.

 

(ii) 
under Section ‎9.2 with respect to Special Representations and with respect to Fundamental Representations will not exceed
the Purchase Price; and

 

(c) The
limitations set forth in clauses (a) and (b) above shall not apply to a Seller in the case of: (x) fraud, intentional misrepresentation
or willful misconduct committed by a Seller, or the Company, or of which the Company or the Seller had actual knowledge prior to the
Closing, which actions may be brought notwithstanding any other provision of this Agreement.

 

9.4 Escrow
Procedures. In the event that a Loss which exceed the Threshold is claimed by the Purchaser, Purchaser may place such claimed
Loss amount in escrow up to an aggregate amount not to exceed USD 300,000, to be held by the Escrow Agent until settled in accordance
with the terms of the Escrow Agreement. In such event the 600,000 Payment shall be temporarily reduced by the amounts placed in escrow.

 

9.5 Certain
Tax and Other Matters.

 

(a) Seller’s
Tax Indemnity. Subject to Section ‎0 above, the Seller with respect to Taxes payable by or on behalf of the Company, agrees
to indemnify, defend and hold harmless Purchaser and the Indemnified Parties against (i) any and all liability for Taxes of the Company
Seller for any taxable period ending on or prior to the Closing Date and with respect to any taxable period that begins before and ends
after the Closing Date (“Straddle Period”), only for the portion thereof ending on the Closing Date (as determined
in accordance with Section ‎9.5(b)), and (ii) any and all withholding Taxes required pursuant to a written demand issued by
a taxing authority, if any, with respect to payments made to the Seller under this Agreement, including any Taxes imposed by any taxing
authority on any Indemnified Party, to the extent that the consideration payable or otherwise deliverable to such Seller under this Agreement
was not reduced by any deductions or withholdings of Taxes required under the Israeli Code (“Tax Withholding Deficit”).

 

    35

     

    

 

(b) Straddle
Period. In the case of any Straddle Period, the amount of Taxes allocable to the portion of the Straddle Period ending on the Closing
Date shall be deemed to be: (i) in the case of Taxes imposed on a periodic basis (such as corporate income Tax), the amount of such Taxes
for the entire period multiplied by a fraction, the numerator of which is the taxable profit attributed to the period in the Straddle
Period ending on and including the Closing Date, and the denominator of which is the taxable profit attributed to the entire relevant
Straddle Period, and (ii) in the case of Taxes not described in clause (i) above, the amount of any such Taxes determined as if such
taxable period ended as of the close of business on the Closing Date.

 

9.6 Sole
Remedy. From and after the Closing, except with respect to any claims for fraud, intentional misrepresentation, or willful misconduct
or criminal conduct or remedies of specific performance, injunction, restraining order or other equitable relief, the indemnification
provided for in this Article 9 shall provide the sole and exclusive monetary remedy with respect to any and all Losses arising
out of breach of representations or warranties by Seller or Company.

 

9.7 Liability
for Company Acts. It is hereby clarified and agreed that, notwithstanding anything to the contrary herein, whether express or
implied, the inclusion of the Company as a party to this Agreement, which, among other things, provides (by itself or by its officers)
representations under Article 4 hereof, undertakes certain commitments and covenants contained in this Agreement (for example to deliver
closing documents, certificates, calculations) prior to and at Closing (“SPA Actions”), does not imply as if
the Company will have any liability toward the Purchaser in connection therewith post-closing. All liability toward the Purchaser in
connection with such SPA Actions made on or prior to Closing shall be, subject to and as of the Closing, assumed by and vested solely
with the Seller pursuant to ‎Article 9.

 

Article
10

TERMINATION

 

This
Agreement may be terminated prior to the Closing, by:

 

(A) mutual
written consent of the Purchaser and the Seller;

 

(B) either
party by providing a written notice of such termination to other Party: (i) if the Closing shall not have occurred on or before December
31, 2022, or (ii) material breach by either Party of any of its obligations or covenants contained herein and the failure of such Party
to cure such breach within thirty (30) days after receipt of written notice from the other Party requesting such breach to be cured.

 

(C) by
Purchaser, in the event of any Material Adverse Effect with respect to the Company.

 

Article
11

GENERAL

  

11.1 Amendments;
Waivers. This Agreement and any schedule or exhibit attached hereto may be amended only by agreement in writing of Purchaser
and the Seller. No waiver of any provision nor consent to any exception to the terms of this Agreement or any agreement contemplated
hereby shall be effective unless in writing and signed by the Party waiving or consenting to the provision and then only to the specific
purpose, extent and instance so provided.

 

    36

     

    

 

11.2 Schedules;
Exhibits; Integration. Each schedule and exhibit delivered pursuant to the terms of this Agreement or any other Transaction Document
shall be in writing and shall constitute a part of this Agreement. This Agreement, together with such schedules and exhibits, constitutes
the entire agreement among the Parties pertaining to the subject matter hereof and supersedes all prior agreements and understandings
of the Parties in connection therewith.

 

11.3 Interpretation.
For all purposes of this Agreement, except as otherwise indicated,

 

(a) all
accounting terms not otherwise defined herein have the meanings assigned under GAAP,

 

(b) pronouns
of either gender or neuter shall include, as and when appropriate, the other pronoun forms,

 

(c) the
words “include” and “including” shall be without limitation and shall be construed
to mean “include, but not be limited to” or “including, without limitation”,

 

(d) references
to Exhibits, Schedules, Articles, Sections and paragraphs shall be references to the Exhibits, Schedules, Articles, Sections and paragraphs
of this Agreement, and

 

(e) the
words “herein,” “hereof” and “hereunder” and other words
of similar import refer to this Agreement as a whole and not to any particular Article, Section or other subdivision.

 

11.4 Governing
Law; Jurisdiction. This Agreement, and any other Transaction Document, their validity, performance, interpretation, breach and
the legal relations between the Parties shall be governed by, construed and enforced only in accordance with the laws of the State of
Israel applicable to contracts made and performed wholly in such State and without regard to conflicts of law doctrines. The competent
courts in Tel Aviv shall have the exclusive jurisdiction over any issue arising from this Agreement and all disputes shall be submitted
to such court only, such that no other legal forum shall have any jurisdiction over issues arising from this Agreement.

 

11.5 Successors;
No Assignment. All of the terms and provisions of this Agreement shall be binding upon, inure to the benefit of and be enforceable
by each of the Parties hereto and their respective heirs, executors, successors and permitted assignees. Neither this Agreement (nor
any Transaction Document) nor any rights or obligations under any of them are assignable by the Seller nor by the Purchaser except for
the Purchaser’s right to assign the right to enforce the undertakings taken by the Seller under Sections 6.1 and 6.2 as described
thereunder.

 

    37

     

    

  

11.6 Headings.
The descriptive headings of the articles, sections and subsections of this Agreement are for convenience only and do not constitute a
part of this Agreement.

 

11.7 Counterparts.
This Agreement and any amendment hereto or any other agreement (or document) delivered pursuant hereto may be executed in one or more
counterparts and by different parties in separate counterparts. All of such counterparts shall constitute one and the same agreement
(or other document) and shall become effective (unless otherwise therein provided) when at least one counterpart has been signed by each
Party and delivered to the other Parties. Electronic transmission (which shall be deemed to include the e-mail delivery of documents
in Adobe or .pdf or similar static format) of any signed original counterpart and retransmission of any signed electronic transmission
shall be deemed the same as the delivery of an original.

 

11.8 Publicity
and Reports. Subject to Section ‎6.2(d), the Company, Seller and Purchaser shall coordinate all publicity relating
to the Transactions contemplated by this Agreement, and neither Party shall issue any press release, publicity statement or other public
notice relating to this Agreement, or the Transactions contemplated by this Agreement, without obtaining the prior consent of the other
Party which shall not be unreasonably withheld (provided that if a Party already publicly released information about the Transactions
following the approval and coordination described above, then the other Parties shall be allowed to publish same information or paraphrase
of it

 

11.9 Parties
in Interest. This Agreement shall be binding upon and inure to the benefit of each party, and nothing in this Agreement, express
or implied, is intended to confer upon any other Person any rights or remedies of any nature whatsoever under or by reason of this Agreement.
Nothing in this Agreement is intended to relieve or discharge the obligation of any third Person to any party to this Agreement.

 

11.10 Notices.
Any notice or other communication hereunder must be given in writing and either (a) delivered in Person (including via courier), (b)
transmitted by electronic telecommunications mechanism:

 

	 	

    If
    to Purchaser or the Company, following the Closing, addressed to:
	Titan
                                            Innovations Ltd.

    Address:
    26 Maskit St., Herzlyia, Israel, 4673326

    Attention:
    Yahav Regev

    Email:
    yahav@titangroup.io

	 	 	 
	 	With
    copies to (which copies shall not constitute notice):	Shibolet
                                            & Co.,

                                            4 Itzhak Sade St.

                                            Tel Aviv 6777520 Israel

                                            Attention:

    Ido
    Shomrony, Adv. I.Shomrony@shibolet.com;

	 	 	 
	 	If
                                            to the Seller

     
	Sky
                                            Sovereign Inc. 

    Attn:
    COMSovereign Holding Corp.

    Address:
    5000 Quorum Drive, Dallas, TX 75254, USA

    Attention:
    David Knight

    Email:
    legal@comsovereign.com

	 	 	 
	 	With
    copies to (which copies shall not constitute notice):	FISCHER
                                            (FBC & Co.)

    146
    Menachem Begin Rd.

    Tel
    Aviv 6492103, Israel

    Attention:
    Galai Sharir, Adv.

    gsharir@fbclawyers.com

 

    38

     

    

 

or
to such other address or to such other Person as either party shall have last designated by such notice to the other party. Each such
notice or other communication shall be effective (i) when delivered in Person, (ii) if given by telecommunication, when transmitted to
the applicable number so specified in (or pursuant to) this Section ‎11.10.

 

11.11 Expenses.
The Seller, on the one hand, and the Purchaser, on the other hand, shall pay their own expenses incident to the negotiation, preparation
and performance of this Agreement and the Transactions contemplated hereby, including but not limited to the fees, expenses and disbursements
of its accountants and counsel and of securing third party consents and approvals required to be obtained by it, and the Seller shall
not pay such expenses through the Company.

 

11.12 Waiver.
No failure on the part of any party to exercise or delay in exercising any right hereunder shall be deemed a waiver thereof, nor shall
any single or partial exercise preclude any further or other exercise of such or any other right.

 

11.13 Disclosures;
Representation By Counsel; Interpretation.

 

(a) No
information or knowledge obtained by Purchaser during the pendency of the Transactions contemplated by this Agreement, including in any
due diligence investigation, shall affect or be deemed to modify any representation, warranty, covenant, condition or obligation under
this Agreement.

 

(b) Each
of the Seller and Purchaser acknowledge that each party to this Agreement has been represented by counsel in connection with this Agreement
and the Transactions contemplated by this Agreement. Accordingly, any rule of Law or any legal decision that would require interpretation
of any claimed ambiguities in this Agreement against the party that drafted it has no application and is expressly waived. The provisions
of this Agreement shall be interpreted in a reasonable manner to effect the intent of Parties.

 

11.14 Severability.
If any provision of this Agreement is determined to be invalid, illegal or unenforceable by any Governmental Entity, the remaining provisions
of this Agreement shall remain in full force and effect; provided, that the essential terms and conditions of this Agreement for all
Parties remain valid, binding and enforceable. In the event of any such determination, then, the Parties agree to negotiate in good faith
to modify this Agreement to fulfill as closely as possible the original intents and purposes hereof. To the extent permitted by Law,
the Parties hereby to the same extent waive any provision of Law that renders any provision hereof prohibited or unenforceable in any
respect.

 

11.15 Injunctive
Relief. Notwithstanding anything herein to the contrary, each of the Parties understands, acknowledges and agrees that in the
event of a breach or threatened breach of any of the covenants and promises contained in this Agreement, the other Parties may suffer
irreparable injury for which there is no adequate remedy at law and will therefore be entitled to seek to obtain injunctive relief, restraining
order, specific performance order or such other equitable relief (other than rescission) enjoining such breach or threatened breach.

 

    39

     

    

 

IN
WITNESS WHEREOF, the Parties have duly executed this Agreement as of the date first written above.

 

	 	PURCHASER:
	 	 	 
	 	By:	/s/ Chaimi Nissel
	 	Name:	Chaimi Nissel
	 	Its:	Chairman
	 	 	 
	 	SELLER:
	 	 	 
	 	By:	/s/ David Knight
	 	Name:	David Knight
	 	Its:	Director
	 	 	 
	 	COMPANY:
	 	 	 
	 	By:	/s/ Shuki Rynski
	 	Name:	Shuki Rynski
	 	Its:	CEO
	 	 	 
	 	PARENT:
	 	 	 
	 	As the sole shareholder of Seller, Parent hereby guarantees the performance of all obligations of the Seller included in this Agreement.
	 	 	 
	 	By:	/s/ David Knight
	 	Name:  	David Knight
	 	Its:	Director

 

 

40Exhibit10.1
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”

EMPLOYMENT AGREEMENT
This employment agreement, which shall include and incorporate by reference any appendix attached hereto, now or in the future (collectively “Agreement”), is entered into on December 22, 2022, (“Effective Date”), by and between ENFUSION LTD. LLC (“Enfusion”), with its principal place of business located at 125 SOUTH CLARK STREET, SUITE 750, CHICAGO, ILLINOIS 60603, and Oleg Movchan, (“Employee”), an individual with a notice address of: [***] (each a “Party” or collectively, the “Parties”).
WHEREAS, Enfusion is in the business of creating and providing software and related products and services to clients in the investment and financial services industry throughout the United States and Global market with offices in Chicago and New York City and affiliate offices in London, Dublin, Hong Kong, Singapore, São Paulo, Shanghai, Sydney, Mumbai, and Bengaluru;
WHEREAS, Enfusion desires to hire Employee to perform certain services as described in this Agreement and any appendix attached hereto, and Employee desires to be hired by Enfusion to perform certain services described in this Agreement and any appendix attached hereto, each in accordance with the terms and conditions of this Agreement as may be amended or supplemented from time-to-time; and,
NOW THEREFORE, in exchange for good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the Parties covenant and agree as follows:
		1.
	Interpretation. Unless the context of this Agreement otherwise requires: (i) a capitalized word has the meaning assigned to it by this Agreement; (ii) “or” will be construed such that the series may include any of the items, all of the items, or any combination of the items; (iii) words in the singular include the plural, and words in the plural include the singular; (iv) provisions apply to successive events and transactions; (v) “hereof,” “hereunder,” “herein,” and “hereto” refer to the entire Agreement and not any section or subsection; (vi) references in this Agreement to sections or annexes are references to the sections of or annexes attached to this Agreement; (vii) “in writing” refers to in written or printed form, facsimile transmission, or e-mail; (viii) the term “include” does not create an exclusive list and should be interpreted, in any variation, as “includes, but is not limited to;” (ix) the phrase “any reason” should be read as “any reason or no reason;” and, (x) the headings in this Agreement are for reference only and shall not limit or otherwise affect the meaning, interpretation, or construction of this Agreement.

		2.
	Employment. Enfusion hereby agrees to employ Employee and Employee hereby agrees to accept Enfusion’s employment offer, each subject to and in accordance with the terms and conditions of this Agreement.

		3.
	Classification of Employment. Employee’s classification as Exempt or Non-Exempt under Fair Labor Standards Act (“FLSA”) shall be determined by Enfusion and any changes to the Employee’s classification shall be communicated by Enfusion to the Employee.

		4.
	Duties. Employee’s initial appointment and non-exhaustive description of duties are described on Appendix 1 (Scope of Employment) and are subject to the terms and conditions of this Agreement. Despite the duties described on Appendix 1, Employee understands and acknowledges that Enfusion, at its sole discretion, has the right to modify or redefine Employee’s duties or title at any time, for any reason.

​
​

​
	
	​
	Chicago
125 South Clark Street
Suite 750
Chicago, IL 60603
	​
enfusion.com

​
​

​

		5.
	Work Hours. Enfusion’s ordinary office hours are 8:00AM to 5:00PM, Monday through Friday. Unless otherwise specified on Appendix 1, Employee’s regular workweek shall be forty (40) hours on a schedule of eight (8) working hours per day, Monday through Friday; however, Employee understands and agrees that from time-to-time and subject to applicable law, Employee may be required to work additional hours, including weekends and holidays, as necessary to support Enfusion’s business. Employee understands and agrees, Employee’s work hours and surrounding terms may be modified at Enfusion’s sole discretion to the furthest extent permitted by applicable law.

		6.
	Location. Employee’s assigned work location (the “Office”) will be described on Appendix 1. Subject to the terms and conditions of this Agreement and applicable law, Employee is required to be present at the Office during Work Hours (defined on Appendix 1).

		7.
	Performance of Duties; Exclusive Service. Employee has a duty of loyalty and care to Enfusion and agrees to perform their obligations faithfully and to the best of their ability. Similarly, Employee hereby agrees to abide by Enfusion’s policies and procedures (as amended from time-to-time) and agrees to devote their business time, attention, and efforts to Enfusion’s business (except for permitted break periods, vacation periods, and reasonable periods of illness or other incapacity). Despite the foregoing sentence, Employee may serve as a director of or otherwise participate in educational, welfare, social, religious, and civic organization, provided that Employee’ service or participation does not: (i) unreasonably interfere with performing their duties; and, (ii) violate any provision of this Agreement. For clarity, while employed by Enfusion, Employee is not allowed to perform duties or services for any other employer, business, or organization (including establishing or maintain their own business or organization) other than as permitted by this Agreement or with the written consent of an Enfusion authorized officer.

a)Business Ideas/Opportunities. During their employment, Employee may come up with or across potential business opportunities related to Enfusion’s business and services (“Business Opportunity”). If so, Employee agrees to promptly disclose any Business Opportunity to Enfusion so that Enfusion has an opportunity to pursue the Business Opportunity. Employee acknowledges and agrees that pursuing a Business Opportunity for Employee’s or another’s benefit, without first disclosing it and getting Enfusion’s prior written approval would be a violation of their duty of loyalty and care to Enfusion and that Employee is prohibited from pursuing a Business Opportunity, whether for Employee’s or another’s benefit, without Enfusion’s prior written approval. Enfusion’s reserves the right to deny Employee’s request to pursue a Business Opportunity in Enfusion’s sole discretion.
		8.
	Compensation and Benefits. Employee is entitled to certain compensation and benefits, which are outlined below and described further on Appendix 1.

a)Salary. Enfusion agrees to pay Employee for services rendered under this Agreement. Employee’s Salary (as defined on Appendix 1) will be paid in accordance with Enfusion’s normal payroll policies and procedures. To be clear, although Employee is paid an annual salary, Employee’s employment is “at-will” (discussed below). Enfusion, at its sole discretion, may adjust Employee’s Salary after the first twelve (12) months of employment and reserves the right to adjust Employee’s Salary from time-to-time.
b)Benefits. During Employee’s employment, except as otherwise expressly provided herein, Employee will be entitled to participate in all employee health, welfare and other benefit plans and programs (“Employee Benefit Plans”) applicable to similarly situated employees of Enfusion, as in effect from time to time, to the extent consistent with applicable law and the terms of the applicable employee
​

​
	
	​
	Chicago
125 South Clark Street
Suite 750
Chicago, IL 60603
	​
enfusion.com

​
​

​

benefit plan. Enfusion reserves the right to amend or cancel any Employee Benefit Plans at any time in its sole and absolute discretion, subject to the terms of the employee benefit plan and applicable law.
c)Vacation. Employee will be subject to Enfusion's Flexible Time Off Policy as outlined in Appendix 1. Employee should use their best efforts not to schedule Flexible Time Off that will conflict with their duties and when possible, agrees to provide Enfusion with at least one (1) to two (2) weeks’ prior notice of any planned vacation subject to the terms of the policy. Enfusion reserves the right, in its sole discretion, to approve or deny any requested Flexible Time Off. Flexible Time Off is subject to certain restrictions on use as outlined in the Enfusion Flexible Time Off Policy.
d)Bonus.
i.Discretionary Bonus. Enfusion may, from time-to-time, in its sole discretion, choose to pay Employee additional compensation as a discretionary bonus. Whether and when a bonus is awarded, and the amount (if any) of bonus awarded, will be determined in Enfusion’s sole discretion on whatever basis and after taking into account whatever factors it considers appropriate at the time. Any bonus is not earned until paid. Therefore, to receive any bonus, Employee must be employed by Enfusion and in good standing on the bonus’s payment date and must not have indicated their intent to resign prior to or on such payment date.
ii.Other Bonus. If the Employee is eligible to receive a non-discretionary (annual performance bonus) or other type of commission-based compensation, then it will be described on Appendix 1.
e)Payments. All payments made to Employee in the course of their employment will be paid in accordance with Enfusion’s normal payroll policies and procedures. Further, all compensation payments made in the course of Employee’s employment will be subject to any applicable withholding requirements or other similar obligations.
f)Expenses. Enfusion will reimburse Employee for out-of-pocket expenses incurred by Employee in the course of their employment pursuant to Enfusion’s reimbursement policy and in each case, subject to applicable law.
Consideration. In consideration for Employee agreeing to Sections 11 and 14 of this Agreement, the Company will provide the employee consideration, including, but not limited to, an at-will employment relationship, or continued at-will employment; training; and access to, or continued access to the Company’s Confidential Information and client, customer and business relationships during Employee’s employment. Employee agrees the consideration outlined in this paragraph is sufficient consideration for Employee’s various obligations under Sections 11 and 14 of this Agreement. Employee understands that acceptance of this Agreement is a condition of employment and that the Company would not offer to employ Employee and grant Employee access to its Confidential Information and client and customer relationships, but for Employee’s acceptance of the terms of this Agreement and acknowledgment that the consideration outlined herein is sufficient consideration for Employee’s obligations under Sections 11 and 14 of this Agreement.
		9.
	Employment Relationship and Termination. “Termination Date” means the date on which Employee ceases work for Enfusion, whether voluntary or involuntary.

​

​
	
	​
	Chicago
125 South Clark Street
Suite 750
Chicago, IL 60603
	​
enfusion.com

​
​

​

a)“AT-WILL” EMPLOYMENT. EMPLOYEE ACKNOWLEDGES AND AGREES THAT THEIR EMPLOYMENT IS “AT-WILL.” THIS MEANS, BOTH ENFUSION AND EMPLOYEE MAY TERMINATE EMPLOYEE’S EMPLOYMENT AT ANY TIME, FOR ANY REASON OR NO REASON, WITHOUT LIABILITY FOR BREACH OF CONTRACT, PROMISSORY ESTOPPEL, SEVERANCE PAY, OR OTHERWISE.
b)Voluntary Termination. Although Employee has the right to terminate their employment at any time for any reason, Employee, if classified as a Level 3, 4 or 5 Employee, agrees to provide Enfusion with at least thirty (30) days’ prior notice to the date on which Employee intends to cease working for Enfusion. If Employee is classified as a Level 2 Employee, Employee agrees to provide Enfusion with at least sixty (60) days’ prior notice to the date on which Employee intends to cease working for Enfusion. If Employee is classified as a Level 1 Employee, Employee agrees to provide Enfusion with at least ninety (90) days’ prior notice to the date on which Employee intends to cease working for Enfusion. Employee’s initial level is contained within Appendix 1 of this Agreement. Upon receipt of Employee's notice of their intent to cease working for Enfusion, Enfusion may, in its sole discretion, choose to reduce Employee's notice period (as described in this paragraph) without additional obligations to Employee.
c)Final Payment. Unless otherwise required by applicable state law, upon Employee’s Termination Date, Enfusion shall provide Employee with a date, no later than Enfusion’s next regular pay date, on which Employee will receive their final payment for all accrued Salary and any other pay owed through the Termination Date.
		10.
	Representations. Employee understands and acknowledges that the following representations and covenants are essential to Enfusion’s decision to enter into this Agreement. Employee represents and warrants to Enfusion as follows:

a)Other than as already disclosed by Employee to Enfusion, as of the Effective Date, Employee is not under any contractual or legal duty or obligation, engagement, understanding, restriction, or commitment with any prior employer, other entity or individual other than Enfusion or its Affiliates ("Other Employer”) that would limit, prohibit, or interfere with Employee’s full and faithful performance of this Agreement, including but not limited to, employment, consulting, confidentiality, non-competition, or non-solicitation agreements or restrictive covenants; Employee certifies that if they have made a disclosure of a contractual or legal duty or obligation, engagement, understanding, restriction, or commitment with any Other Employer that would limit, prohibit, or interfere with Employee’s full and faithful performance of this Agreement, including but not limited to, employment, consulting, confidentiality, non-competition, or non-solicitation agreements or restrictive covenants, that their disclosure was a complete disclosure of any applicable terms.
b)Employee does not have any inventions or intellectual property obligations which may affect assignment under Section 13, other than what Employee has disclosed in Appendix 2;
c)If applicable, Employee has disclosed any Other Employers existing as of the Effective Date;
d)If applicable, Employee has complied with all duties imposed on Employee by their former employer with respect to termination of their employment;
e)Employee is free to enter this Agreement and commence employment with Enfusion;
​

​
	
	​
	Chicago
125 South Clark Street
Suite 750
Chicago, IL 60603
	​
enfusion.com

​
​

​

f)Employee understands and acknowledges the offer of employment made pursuant to this Agreement is made only to Employee for their personal services, and at no time has Employee been authorized to recruit, induce, entice, or offer employment at Enfusion to any other person;
g)Employee covenants not to use, disclose, or induce the use of, any trade secret, confidential information, or proprietary information that belongs to any third party in the performance of Employee’s employment under this Agreement, unless Employee has prior written consent from the owner of the protected information (which, Employee agrees to provide such written consent to Enfusion); and,
h)Employee is not aware of: (i) any pending internal, criminal, civil, regulatory, or self-regulatory organization investigations involving Employee or any of Employee’s activities at any former employer or in relation to or arising out of Employee’s prior employment ; (ii) any pending customer complaints or customer arbitrations involving any of Employee’s activities at any former employer or in relation to or arising out of Employee’s prior employment; or, (iii) any circumstances that might lead to any of the matters described in this subsection. If Employee is aware of any such issues, Employee has disclosed such in writing to Enfusion’s Chief Human Resources Officer at least seven (7) days prior to the parties entering into this Agreement.
		11.
	Confidential Information and Confidentiality.

a)Employee acknowledges and agrees that through their employment, he or she will be provided, obtain, or be exposed to proprietary or non-public information relating to Enfusion’s business, which is confidential in nature. Such information includes, client lists or client related information, information related to or concerning Enfusion’s products and services; fees, costs, and pricing structures; market studies; business plans and investment analyses; designs and specifications; data and analyses; drawings, photographs, and reports; computer software, object code, source code, operating systems, applications, algorithms, and program listings; flow charts, manuals, and documentation, ideas, images, text, music, movies, concepts, video, and websites; databases; accounting and business methods; inventions, devices, new developments, methods, and processes, (whether patentable or non-patentable and whether or not reduced to practice); investor or ownership information, Client and Prospective Client information; copyrightable works; technology and trade secrets; historical financial statements, financial projections, and budgets; personnel training techniques and materials; and any other personal, business, financial, or technical information, data, patents, or ideas relating to the proprietary information observed by, or disclosed to, Employee, whether in oral, written documents, memoranda, reports, or correspondence in graphic or machine-readable form, or otherwise in the course of, or in connection with, Employee’s employment with Enfusion (individually and collectively “Confidential Information”).
b)Employee hereby agrees that he or she will not disclose nor use at any time; before, during, or after their employment with Enfusion; any Confidential Information of which Employee is or becomes aware of, whether or not such information is developed by Employee, except to the extent such disclosure or use is directly related to or required for Employee’s performance of their employment duties. Further, Employee agrees he or she will take all reasonable and appropriate steps to safeguard the Confidential Information and to protect it against disclosure, misuse, espionage, loss, or theft and will not disclose or use any Confidential Information except as reasonably necessary to perform Employee's duties for the Company, or as required by law. Employee further agrees not to otherwise transmit or download any Confidential Information to Employee's personal computer, cellular telephone, or other electronic device, or otherwise remove Confidential Information from the Company's premises or Company-owned computer, unless Employee secures the Company's specific authorization in advance and takes appropriate
​

​
	
	​
	Chicago
125 South Clark Street
Suite 750
Chicago, IL 60603
	​
enfusion.com

​
​

​

steps to protect such information. Employee understands and agrees that all Confidential Information, including documents, records, and electronic files, to which Employee has access as a result of Employee's employment by the Company are the exclusive property of the Company. Employee also acknowledges and agrees that all Confidential Information, and all copyrights, trademarks, patents and other rights in connection therewith, shall be the sole property of the Company and its assigns. For clarity, nothing herein is intended to prevent Employee from disclosing information that Employee has a legal right to disclose.
c)Exceptions. Confidential Information shall not include any information that: (i) was in the possession of, or demonstrably known by, (in each case without restriction on its use or disclosure) the Employee prior to their receipt of such information; (ii) any information independently known by Employee without access to or reliance upon any Confidential Information, including the general skills, knowledge and experience acquired by the Employee before and/or during employment with the Company; (iii) was lawfully disclosed to Employee following the end of their employment with Enfusion by a third party under no known obligation of confidentiality; (iv) is in the public domain at the time of disclosure, or thereafter becomes in the public domain, other than as a result of disclosure by Employee in violation of this Agreement.
d)In the event Employee is required under a subpoena, court order, statute, law, rule, regulation, or other similar requirement, (“Legal Requirement”) Employee shall do so only to the extent required by the Legal Requirement, must provide prompt written notice to Enfusion of the disclosure to the extent not precluded by law, and must designate the information as Confidential Information when disclosing such information. Further, when legally permissible, the Employee shall notify Enfusion of what Confidential Information was disclosed under such Legal Requirement.
e)Defend Trade Secrets Act of 2016 (DTSA) Notice. Notwithstanding any other provision of this Agreement, pursuant to Section 7 of the DTSA, the Employee cannot be held criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade secret that: (1) is made: (A) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (B) solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. (ii) If Employee files a lawsuit for retaliation by Company for reporting a suspected violation of law, Employee may disclose Company’s trade secrets to Employee’s attorney and use the trade secret information in the court proceeding if Employee: (1) files any document containing the trade secret under seal; and (2) does not disclose the trade secret, except pursuant to court order.
f)Violation of Law. If Employee believes Enfusion has committed or is committing a violation of law, although not required, he or she is asked to first report the possible violation to Enfusion’s executive leadership so that Enfusion may take the proper corrective actions. Despite the foregoing, Employee is free to report possible violations, file a charge with, or participate or cooperate with any governmental agency or entity, including but not limited to the EEOC, the Department of Justice, the Securities and Exchange Commission, Congress, or any agency Inspector General, or make any other disclosures that are protected under the whistleblower, anti-discrimination or anti-retaliation provisions of federal, state or local law or regulation; provided further, the Employee does not need the prior authorization of the Company to make any such reports or disclosures, and the Employee is not required to notify the Company that the Employee has made such reports or disclosures.
g)Trading. Employee understands and agrees he or she is not permitted to use Enfusion’s or Clients’ Confidential Information on their behalf, on the behalf of others, or to assist others in trading securities.
​

​
	
	​
	Chicago
125 South Clark Street
Suite 750
Chicago, IL 60603
	​
enfusion.com

​
​

​

Employee further acknowledges that to use Enfusion’s or Client’s Confidential Information for personal financial benefit or to “tip” others who might make an investment decision on the basis of this information is not only prohibited and unethical, but is also illegal.
		12.
	Company Property. Upon Enfusion’s request or Employee’s Termination Date, Employee shall, to the extent such materials are in Employee’s possession or under Employee’s control, promptly deliver to Enfusion: (i) all original and any copies of emails, employee training materials, records, agreements, manuals, books, blank forms, documents, letters, memoranda, notes, notebooks, reports, data, tables, or calculations, which are the property of Enfusion or its Affiliates and that relate, in any way, to the business, products, policies, practices, or techniques thereof, including any strategies; (ii) all other Enfusion property, including any Enfusion issued credit cards, identification, keys, computers, cell phone, or other equipment; (iii) all Confidential Information of Enfusion or its Affiliates, including all documents that, in whole or in part, contain any Confidential Information of Enfusion or its Affiliates or their respective clients or licensors; and (iv) all proprietary information, intellectual property and trade secrets of Enfusion or its Affiliates or their respective clients or licensors. In addition, if applicable, Employee shall promptly cancel or transfer to himself or herself any telecommunications services for which Enfusion was directly paying. Nothing in this Section shall prohibit Employee from retaining papers or materials that are solely of a personal nature, including copies of documents showing their compensation or reimbursable expenses and a copy of this Employment Agreement.

		13.
	Intellectual Property. (“Intellectual Property”) means any and all intellectual property in any form or stage of development, including any innovation, discovery, idea, concept, design, prototype, product configuration, invention, improvement, modification, patentable subject matter, method, process, technique, procedure, system, plan, model, program, software or code, source code, algorithms, data, specification, drawing, images, text, music, movies, video, websites, diagram, flow chart, documentation, know-how, work of authorship, copyrightable subject matter, derivative work, trademark or trade name, and any other subject matter, material, or information that qualifies or is considered by Employer to qualify for patent, copyright, trademark, trade dress, trade secret, or any other protection under any law providing or creating intellectual property rights, including the Uniform Trade Secrets Act. Intellectual Property also includes Confidential Information learned, obtained, or developed in connection with Employee’s employment, such as specifications, financial data, personnel information, market information, business arrangements, and other non-public information of Employer described in Section [11] of this Agreement. EMPLOYEE AGREES THAT ANY INTELLECTUAL PROPERTY CONCEIVED OR MADE BY EMPLOYEE, WHETHER ALONE OR WITH OTHER, DURING THE TERM OF EMPLOYEE’S EMPLOYMENT WITH ENFUSION RELATING IN ANY MANNER TO THE BUSINESS, BUSINESS PLANS, OR STRATEGIES OF ENFUSION OR ITS AFFILIATES, SHALL BE THE EXCLUSIVE PROPERTY OF ENFUSION OR SUCH AFFILIATE. WITHOUT LIMITING THE FOREGOING, TO THE EXTENT ANY COPYRIGHTABLE WORK IS INCLUDED IN THE FOREGOING, IT WILL BE DEEMED ‘A WORK MADE FOR HIRE” FOR THE BENEFIT OF ENFUSION OR SUCH AFFILIATE UNDER SECTION 201(b) OF THE 1976 U.S. COPYRIGHT ACT, AS AMENDED, OR OTHER SIMILAR APPLICABLE STATE OR FOREIGN OR INTERNATIONAL LAWS. FURTHER, EMPLOYEE AGREES THAT ALL INVENTIONS, HE OR SHE DEVELOPS OR DEVISES (WHETHER INDIVIDUALLY OR IN CONCERT WITH OTHERS): (i) USING ENFUSION’S EQUIPMENT, SUPPLIES, RESOURCES, OR CONFIDENTIAL INFORMATION; (ii) RESULTING FROM WORK HE OR SHE PERFORMS OR PERFORMED FOR ENFUSION; OR, (iii) RELATING TO ENFUSION’S CURRENT OR PLANNED RESEARCH OR DEVELOPMENT WILL BE ENFUSION’S SOLE AND EXCLUSIVE PROPERTY. ACCORDINGLY, EMPLOYEE HEREBY ASSIGNS ALL INTELLECTUAL PROPERTY RIGHTS, TITLE, AND INTERESTS TO ENFUSION AND WAIVES ANY MORAL RIGHTS IN THE INTELLECTUAL PROPERTY TO THE FURTHEST EXTENT PERMITTED BY LAW.

​

​
	
	​
	Chicago
125 South Clark Street
Suite 750
Chicago, IL 60603
	​
enfusion.com

​
​

​

		14.
	Restrictive Covenants. Employee understands and recognizes that Enfusion is engaged in a highly competitive business and has spent a considerable amount of time, effort, and resources building its business, products, client base (domestically and internationally), and training its employees. Further, Employee through their employment will receive training regarding and have access to Enfusion’s (and its clients’ and licensors’) Confidential Information (as defined above), trade secrets, and sensitive proprietary business methods or data, customer lists, and other valuable business information. Employee acknowledges and agrees that Enfusion has a legitimate business interest in protecting its goodwill, client and employee base, Confidential Information, trade secrets, and other proprietary information. Accordingly, Employee agrees to be bound by the following restrictive covenants (“Restrictive Covenants”), which are reasonably tailored to protect Enfusion’s legitimate interests from improper and unfair competition, and will not unreasonably impair or infringe on Employee’s right to work or earn a living after Employee’s Termination Date:

a)Definitions: For purposes of this section, the following terms are defined as follows:
i. (“Client”) means a person or organization who has retained, in writing or otherwise, Enfusion or any of its Affiliates to perform a service for compensation, which is, is related to, or is an extension of Enfusion’s or its Affiliates’ normal line of business and which Employee was involved; and,
ii.(“Prospective Client”) means a person or entity that has not yet retained, in writing or otherwise, Enfusion or any of its Affiliates to perform a service for compensation as described above when defining Clients, but instead, is a person or entity that Enfusion or any of its Affiliates reasonably expect to do so by virtue of Prospective Client’s solicitation of Enfusion or its Affiliates or Enfusion’s or its Affiliates’ targeted, direct solicitation of that person or entity within a six (6) month period immediately prior to Employee’s Termination Date.
b)Non-solicitation of Enfusion’s Employees. Throughout Employee’s employment with Enfusion and for a period of one (1) year, to commence on Employee’s Termination Date, Employee agrees not to: directly or indirectly, through any person or entity, or as an agent for any person or entity, authorize, encourage, suggest, or approve any person or entity to employ or cause to be employed, entice, induce, or solicit employment or engagement, in any capacity, any person that Employee had contact with and who is employed by Enfusion or any of its Affiliates or was employed or engaged by Enfusion or its Affiliates within three (3) months of the solicitation. While there is no geographic restraint, Employee understands and acknowledges that the restriction prohibiting solicitation of Enfusion employees is necessary and reasonable based upon Enfusion’s global presence and to protect Enfusion’s legitimate interest in its employee base and the resources utilized in training and maintaining such employee base.
c)Non-solicitation of Enfusion’s Clients. Throughout Employee’s employment with Enfusion and for a period of one (1) year, to commence on Employee’s Termination Date, Employee agrees not to: directly or indirectly, through any person or entity, or as an agent for any person or entity, authorize, encourage, suggest, or approve any person or entity to directly or indirectly, through any person or entity, or as an agent for any person or entity, or authorize, encourage, suggest, or knowingly approve any person or entity to, induce, attempt to induce, or entice any Client (as defined above) or Prospective Client (as defined above), in whole or in part, from doing business with Enfusion or any such Affiliate, regardless of which party initiates the contact or communication; or directly or indirectly, or through any person or entity, authorize, encourage, suggest, or knowingly approve any person or entity to, solicit, communicate with, contact, sell or render assistance, services or products to any Client or Prospective Client that would
​

​
	
	​
	Chicago
125 South Clark Street
Suite 750
Chicago, IL 60603
	​
enfusion.com

​
​

​

interfere with, take away, divert, or urge any Client or Prospective Client to discontinue, in whole or in part, business with Enfusion or any of its Affiliates. While there is no geographic restraint, Employee understands and acknowledges that the restriction prohibiting solicitation of any Enfusion Client or Prospective Client is limited to those Clients or Prospective Clients with whom Employee worked, to whom Employee marketed or sold services or products, or about whom Employee received Confidential Information, as such would give Employee an unfair competitive advantage. Employee agrees this restriction is necessary and reasonable, without regard to geographic constraint, based upon the Employee’s knowledge and/or interaction with the Client or Prospective Client and to protect Enfusion’s legitimate interest in protecting its business relationships.
d)Non-compete. Employee understands and recognizes that: (i) Enfusion has spent a considerable amount of time and resources into training Employee; and, (ii) Employee will gain access to or knowledge of confidential and proprietary information and of practices, successes, and failures during the course of their employment; and, (iii) Employee will build relationships with Enfusion clients or prospective clients through their employment with Enfusion, made possible through Enfusion’s brand and resources, each of which Enfusion has a legitimate interest in protecting and Enfusion’s competitors or prospective competitors will gain an unfair advantage by obtaining the benefit of such foregoing investments made into and interests obtained by Employee. Therefore, throughout Employee’s employment with Enfusion and throughout the Restricted Period (as defined below), Employee agrees not to, directly or indirectly, alone or in association with or on behalf of any other person or entity, engage in any Competitive Activity (as defined below) (“Restricted Employment”).
i.Restricted Period. (“Restricted Period”) means a period of twelve (12) months to commence on Employee’s Termination Date.
ii.Competitive Activity. (“Competitive Activity”) means:
		1.
	Engaging in a Competitive Business (as defined below) directly or indirectly, on Employee’s own behalf or on the behalf of another;

		2.
	Providing services, similar or related to any services Employee provided to Enfusion while employed by Enfusion, to any person engaged in a Competitive Business, whether as an employee, consultant, officer, director, manager, partner, principal, agent, representative, or in any other capacity; or,

		3.
	Controlling (by contract, equity ownership, or otherwise), investing in (except as the owner of up to 3% of the securities of a publicly-traded entity), or providing other financial support to any person engaged in a Competitive Business.

iii.Competitive Business. (“Competitive Business”) means:
		1.
	Asset Management Software, including (a) portfolio management system; (b) order management system; (c) execution management system; (d) fund accounting system; or (e) fund risk management system, or any combination of the foregoing or any software substantially similar to any new software offering Enfusion offers or proposes to offer during Employee’s employment at Enfusion and in which Employee was involved in or received Confidential Information or trade secrets regarding; or

​

​
	
	​
	Chicago
125 South Clark Street
Suite 750
Chicago, IL 60603
	​
enfusion.com

​
​

​

		2.
	Any middle- or back-office services or servicing tied to Enfusion’s software that Enfusion offers or proposes to offer during Employee’s employment at Enfusion and in which Employee was involved in or received Confidential Information or trade secrets regarding, or any other similar software that is an alternative to or competes with Enfusion’s managed services offering, whether in whole or in part; or

		3.
	Any other business or extension of a line of business in which Enfusion was engaged at any time during Employee’s employment, or in which Enfusion plans to engage or is considering plans to engage at the time of the Termination Date (as evidenced in writing) and in which Employee was involved or about which Employee received Confidential Information or trade secrets.

e)Notice. During the Restricted Period, Employee shall notify any other employers or prospective employers of their obligations under this Agreement before Employee begins working for such employer and further, agrees to simultaneously deliver a copy of such notice to Enfusion in accordance with Section 19 (Notices). Further, Employee agrees that Enfusion may also notify such other employers or prospective employers of Employee’s obligations under this Agreement. Employee agrees to inform Enfusion of the name, address, and telephone number of Employee’s supervisor at each subsequent employer to whom Employee reports this Agreement during the Restricted Period.
f)Undue Hardship. If Employee believes in good faith that the provisions in this Section will prevent him or her from obtaining a new job due to its categorization as Restricted Employment, Employee may notify Enfusion in writing, providing reasonable details about the proposed responsibilities of the new job (without disclosing another person’s Confidential Information). The Parties agree to discuss whether appropriate accommodations can be made to balance the protection of Enfusion’s business interests and Employee’s desire to engage in Restricted Employment, and any appropriate adjustments to the payments described above. Except to the extent required by applicable law, Enfusion is under no obligation to modify the restrictions in this Section, but may do so in its sole and absolute discretion.
g)General. For the avoidance of doubt, the Restrictive Covenants contained in this Agreement are in addition to, and not in lieu of, any other restrictive covenants or similar covenants or agreements between the Employee and Enfusion. The above-described restrictions are narrowly tailored to protect Enfusion’s legitimate business interests. The restrictions shall only apply to competitive employment in a capacity that is related to or requires the same or similar skills or knowledge necessary to have performed Employee’s duties at Enfusion or any role similar or related to any role held by Employee while employed at Enfusion.
h)Client Competition. Enfusion will spend a considerable amount of time and resources making Employee an expert of Enfusion’s products and service offerings and has a legitimate interest in protecting such investment in Employee. To protect its legitimate interest and to prevent clients from circumventing and eliminating the need for Enfusion’s services, (whether explicitly or under the guise of reverse engineering) through hiring Employee, Employee agrees that for a period of six (6) months to commence on Employee’s Termination Date, Employee will not, directly or indirectly, accept employment or perform services or duties, paid or unpaid, from any of Enfusion’s Clients or Prospective Clients, provided that Employee had contact with the Client or Prospective Client during their employment and to the extent such employment would be in a capacity substantially similar to the capacity in which the Employee worked for Enfusion. Employee further acknowledges the employment opportunities that Employee could get without violating this Agreement, including, by way of example only, the immense number of hedge funds, asset
​

​
	
	​
	Chicago
125 South Clark Street
Suite 750
Chicago, IL 60603
	​
enfusion.com

​
​

​

managers, fund administrators, fund of funds, and other financial services or investment companies, and that as such he or she will be able to earn a livelihood without violating this Agreement.
i)Extension of Restricted Period. In the event of any violation of any Restrictive Covenant, the restricted period of the covenant that was violated shall be extended by a period of time equal to the period beginning when such violation commenced and ending when the activities constituting such violation have ceased, such that Enfusion gets the full benefit of the bargain with respect to the agreed upon period of restriction.
		15.
	Remedies. Employee acknowledges and agrees that due to the unique nature of Enfusion’s business, Employee’s breach of any obligation may result in irreparable and continuing harm to Enfusion, for which monetary damages may be inadequate to compensate or make Enfusion whole. Therefore, Employee agrees Enfusion is entitled to seek injunctive relief or specific performance to enforce the terms of this Agreement without the necessity of posting a bond. Employee further agrees Enfusion shall also have any other right or remedy available to it under law or in equity including the right to seek and recover monetary damages for lost profits and other compensable damages. Should any court of competent jurisdiction determine that Employee has breached any of the provisions as contained in this Agreement, Enfusion shall have a right to collect, in addition to any monetary damages awarded to it, all of its reasonable attorneys’ fees and costs incurred in connection with its efforts to enforce this Agreement, including pre-litigation efforts. Employee agrees that, if Enfusion seeks preliminary or emergency injunctive relief, and obtains same in whole or in part, the Company shall be entitled to an award of its attorney fees, expenses, and costs incurred in connection therewith upon the entry of the order granting said preliminary or emergency injunctive relief, in addition to any such fees and costs that may be incurred and awarded with respect to any subsequent proceedings in said action.

		16.
	Voluntary Agreement. Employee represents that Employee has carefully read, considered and understands the scope and effect of the provisions of this Agreement and that Employee is fully aware of the legal and binding effect of this Agreement. This Agreement is executed voluntarily by Employee and without any duress or undue influence on the part or behalf of the Company. Employee further acknowledges and agrees that Employee has been provided sufficient time to review the Agreement and consult with an attorney or legal representative regarding the Employee’s rights and obligations under this Agreement. In doing so, Employee acknowledges and agrees, the restrictions set forth in this Agreement impose a fair and reasonable restriction on Employee, reasonably necessary to protect Enfusion’s and its officers’ directors’, members’, and employees’ interests, business, and goodwill.

		17.
	Severability. If any provision of this Agreement is found to be unenforceable or contrary to law; including if any provision concerning time, scope, or geographic restrictions are deemed by a court with competent jurisdiction to be overly broad; the provision in question should be reformed to the minimum extent necessary to correct any invalidity while preserving to the maximum extent, the rights and commercial expectations of the Parties. The remaining portions of this Agreement will remain in full force and effect. Further, every provision of this Agreement shall be construed as independent agreements between Enfusion and Employee. Therefore, any claim or cause of action Employee may have against Enfusion, whether predicated on this Agreement or otherwise, shall not constitute a defense to prohibit the enforcement of any other provision or covenant.

		18.
	Counterparts. This Agreement, and any amendment thereto, may be executed in one or more counterparts and by the Parties hereto in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together, shall constitute one and the same Agreement.

​

​
	
	​
	Chicago
125 South Clark Street
Suite 750
Chicago, IL 60603
	​
enfusion.com

​
​

​

Facsimile, PDF, and any other digital or electronic signatures to this Agreement shall have the same effect as original or wet signatures. If executed in counterparts, this Agreement or any amendment, will not be effective or enforceable until signed by both Employee and an authorized representative of Enfusion.
		19.
	Notices. All notices, requests, claims, demands, and other communications under this Agreement, (collectively “Notices”), must be in writing and sent to the person and address designated in this Section. Any Notices must be hand-delivered, sent by an internationally recognized overnight courier service, sent via e-mail, or sent via registered or certified mail with postage pre-paid and return receipt requested. Notices will be considered given or made upon receipt.

​
	Notices to Enfusion: 
	    
	Notices to Employee:

	Enfusion, LLC
125 S. Clark Street, Suite 750
Chicago, IL 60603
Attn: Human Resources
Phone: 312.253.9800
E-mail: HR@enfusion.com
	​
	See Appendix 1 (Scope of Employment)

​
Employee agrees to provide an updated address to Enfusion at the time of termination and if that address changes during the period of restriction following the Employee’s termination to provide Enfusion the updated address. In the event Enfusion is unable to locate Employee at their last known residence, Employee agrees Enfusion may seek injunctive relief or specific performance without personal service on Employee, so long as Enfusion uses reasonable efforts to first locate Employee.
		20.
	Entire Agreement. This Agreement constitutes the entire agreement between the Parties with respect to its subject matter and (to the extent permissible by law) supersedes all prior agreements, proposals, communications, representations, writings, negotiations, or understandings with respect to that subject matter. All terms, conditions, and warranties not stated expressly in this Agreement, and which would in the absence of this provision be implied into this Agreement by statute, common law, equity, trade, custom or usage or otherwise, are excluded to the maximum extent permitted by law.

		21.
	Governing Law. The legal relations between the Parties hereto and any dispute arising under or in connection with this Agreement, or breach thereof, whether sounding in contract, tort, or otherwise, shall be governed by and construed in accordance with the laws of the United States of America and the State in which the employee’s assigned Office is located (provided in Appendix 1), regardless of any laws that might otherwise govern under applicable choice-of-law principles. Any claim, legal proceeding, or litigation arising out of or in connection with this Agreement or the relationship between Enfusion and Employee will be brought solely in the jurisdiction in which the Office is located, regardless of any laws or rules that might otherwise govern under applicable forum non conveniens principles. Any claim brought in any other jurisdiction or forum is precluded. ACCORDINGLY, BOTH PARTIES HEREBY CONSENT TO THE EXCLUSIVE JURISDICTION OF THE FEDERAL AND STATE COURTS LOCATED WITHIN THE JURISDICTION IN WHICH THE OFFICE IS LOCATED.

		22.
	No Waiver. No waiver, of any of the terms of this Agreement, will be valid unless in writing, explicitly stated as such, and signed by the party waiving its rights. Any forbearance or delay by either party to enforce any of its rights under this Agreement will not be construed as a waiver to enforce any such rights pertaining

​

​
	
	​
	Chicago
125 South Clark Street
Suite 750
Chicago, IL 60603
	​
enfusion.com

​
​

​

to the occurrence in question or any other occurrence. The waiver, by any Party, of any breach of covenant will not be construed as a waiver of any succeeding breach of the same or any other covenant.
		23.
	Assignment. Enfusion may assign this Agreement or its rights under this Agreement to - and Employee may be employed by - any affiliate or subsidiary of Enfusion, or entity that acquires all or substantially all of Enfusion’s assets or acquires a department or line of business of Enfusion that Employee works within, or that is otherwise a successor in interest to Enfusion. This Agreement may not be assigned by Employee, except that Employee’s rights to compensation and benefits hereunder, subject to the limitations of this Agreement, may be transferred by will, by operation of law or as required by the law or a court order.

		24.
	Compliance with Section 409A. This Employment Agreement is intended to comply with, (or be exempt from), Section 409A of the Internal Revenue Code of 1986, as amended, to the extent applicable, and shall be administered and interpreted accordingly. To further clarify, this Section is in no way intended to change that bonuses, if any, are earned upon payment.

		25.
	Binding Agreement. This Agreement shall be binding upon and shall inure to the benefit of both Enfusion and Employee and their respective successors, assigns, heirs, and legal representatives.

		26.
	Terms of Acceptance. This Agreement is conditioned upon and subject to: (i) confirmation that Employee is not a subject to any contractual or other legal restrictions that would prevent or impair their ability to perform the duties of the position offered under this Agreement; (ii) Enfusion’s satisfactory completion of a background investigation, credit check (where appropriate and allowed by law), and reference check (where appropriate); and, (iii) Enfusion’s receipt of Employee’s acceptance of the terms and conditions of this Employment Agreement on or before the close of business on December 28, 2022.

Signature Page to the Employment Agreement between Enfusion Ltd. LLC and Oleg Movchan made effective on December 22, 2022.
IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed as of the Effective Date written above.
​
	Enfusion Ltd. LLC
​
	Employee

	Signature: /s/ Bronwen Bastone
	Signature: /s/ Oleg Movchan

	​
	​

	Name: Bronwen Bastone
	Name: Oleg Movchan

	​
	​

	Title: Chief People Officer
	Date: December 22, 2022

	​
	​

	Date: December 22, 2022
	​

​
​

​
	
	​
	Chicago
125 South Clark Street
Suite 750
Chicago, IL 60603
	​
enfusion.com

​
​

​

Third Party Intellectual Property (IP) Agreement
Dear Oleg,
We are excited to have you join the Enfusion team. As a company, it is very important to us that we respect others’ intellectual property and contractual rights. As part of your onboarding process, please review this letter as it is a topic we hold dearly. Once you have reviewed, feel free to ask any questions you might have. If you do not have any questions, please acknowledge the letter by signing in the designated area located at the bottom of the page.
If you have not done so already, to the extent you may be subject to any enforceable restrictive covenants or contractual limits on: i) your ability to solicit former clients or colleagues; ii) your possession, transfer, or use of confidential information; and, iii) your possession, transfer, or use of trade secret information, Enfusion requires that you disclose the nature of such covenants or contractual limitations before you commence employment. It is important to understand, you are personally responsible for complying with such covenants and limitations until they expire (if at all).
In addition to making Enfusion aware of any covenants or limitations you are subject to, we want to reiterate that you should not remove any trade secrets or confidential written or electronic materials from your current or prior employers. Likewise, you should not bring any such materials to Enfusion. You may not use any confidential or trade secret information you obtained during any prior employment in your work with Enfusion. To the extent the information was maintained as confidential by your previous employer(s), confidential and trade secret information includes, without limitation, any information about competitor marketing strategies, product development, and pricing information, as well as customer and personnel lists and contact information.
If you receive instruction or work from anyone at Enfusion or its affiliates (e.g., Enfusion’s international offices) that you believe would cause you to violate any agreements or covenants with a prior employer or your obligations to Enfusion, you should immediately disclose the matter to your office lead or Enfusion executive leadership, including Enfusion legal. It is very important that you take action under such circumstances because failure to abide by these expectations could result in you being liable to your former employer, withdrawal of Enfusion’s conditional offer of employment, or termination of any employment accepted.
Acknowledged and Accepted:
By Employee
Signature: /s/ Oleg Movchan
Name: Oleg Movchan
Date: December 22, 2022
​

​
	
	​
	Chicago
125 South Clark Street
Suite 750
Chicago, IL 60603
	​
enfusion.com

​
​

​

Scope of Employment
APPENDIX 1 to Employment Agreement
Reference is made to the “Employment Agreement” entered into by and between Enfusion Ltd. LLC (“Enfusion”) and Oleg Movchan (“Employee”) on December 22, 2022 (as may be amended from time-to-time, the “Agreement”). The Parties hereby agree that this Appendix 1 shall be subject to and controlled by the terms and conditions of the Agreement, which shall be incorporated by reference into this Appendix 1. If there is any inconsistency between the terms of the Agreement and this Appendix 1, the terms of the Agreement shall prevail. Further, all capitalized terms used but not defined in this Appendix 1 shall be construed in accordance with the Agreement. For purposes of the ongoing employment relationship between Employee and Enfusion, as of the Commencement Date, this Agreement replaces both the employment agreement entered into by Employee and Enfusion on August 21, 2022 and also the restrictive covenant agreement entered into on September 20, 2022.
		1.
	Commencement Date of Employment. The Employee’s first day of work under the terms of this agreement will be on December 22, 2022 (“Commencement Date”) following his appointment by the Board of Directors.

		2.
	Appointment & Duties. Employee shall serve as Chief Executive Officer and report to the Board of Directors.

		3.
	Work Hours. During an ordinary work week, Employee shall be available during Enfusion’s ordinary office hours described under Section 5 of the Agreement (“Work Hours”).

		4.
	Office. Employee is initially assigned to Enfusion’s office located in Chicago. Enfusion agrees to allow Employee to work from his home on a full-time basis.

		5.
	Status. Employee will be classified as an EXEMPT employee, which means Employee will not be eligible for overtime pay for hours worked in excess of forty (40) hours in any given week.

		6.
	Pay Cycle. As an Exempt employee, Employee will ordinarily receive payment for services rendered twice per month, in accordance with Enfusion’s ordinary payroll policies and procedures.

		7.
	Salary. Employee agrees to accept a base salary to be paid at an annualized rate of $650,000.00 US Dollars (“Salary”). The Salary is paid less applicable deductions and withholdings. Employee’s Salary will be paid in accordance with Enfusion’s normal payroll policies and procedures.

		8.
	Voluntary Termination Notice. Employee is initially classified as a Level 1 Employee. Although Employee has the right to terminate their employment at any time for any reason, as a Level 1 Employee, Employee agrees to give 90 -days’ prior notice to the date on which Employee intends to cease working for Enfusion.

		9.
	Other.

Annual Performance Bonus
In addition to Employee’s Salary, Enfusion may reward Employee’s exemplary performance and the performance of Employee’s group through the award of an annual performance bonus (“Bonus”). Bonus awards will also reflect the company’s overall performance. Employee has a target Bonus of $400,000 (where paid at 100% of target) (less, where applicable, deductions and withholdings). The award of any Bonus shall be conditioned upon: (1) Employee’s satisfactory, as determined solely by Enfusion, meeting of
​

​
	
	​
	Chicago
125 South Clark Street
Suite 750
Chicago, IL 60603
	​
enfusion.com

​
​

​

conditions and goals (relating both to Enfusion’s performance and Employee’s individual performance) to be communicated to Employee by Enfusion upon the commencement of Employee’s employment with Enfusion (and updated at times throughout Employee’s tenure); (2) Enfusion’s performance; and (3) Employee being in “active working status” at the time any Bonus is awarded. For purposes of this provision, “active working status” means that the Employee has not resigned (or given notice of Employee’s resignation) or been terminated (or been given notice of Employee’s termination).
Initial Grant – Performance-Based Restricted Stock Unit
On the Commencement Date, Enfusion shall grant Employee 250,000 performance-based restricted stock units ("RSU") subject to the Enfusion 2021 Stock Option and Incentive Plan (the "Plan"). Any grant of performance-based RSUs shall be pursuant to a separate Performance-Based Restricted Stock Award Agreement ("Agreement") and shall vest in accordance with the terms set forth in that Agreement and subject to all conditions and limitations contained in the Agreement and Plan. This grant shall vest contingent on the following: (i) 125,000 performance-based RSUs (50%) vesting upon the achievement of a 10-day moving average of Enfusion’s closing stock price of $17.00 at any point on or before the three year anniversary of the Commencement Date and (ii) 125,000 performance-based RSUs (50%) vesting upon the achievement of a 10-day moving average of Enfusion’s closing stock price of $25.00 at any point on or before the three-year anniversary of the Commencement Date. In the event that (i) and/or (ii) do not occur on or before the three year anniversary of the Commencement Date, any unvested performance-based RSUs will be forfeited at that time. In the event of a “Sale Event” (as defined in the Plan), the terms contained in the Performance-Based Restricted Stock Award Agreement shall govern. In the event of a termination of employment prior to the achievement of either or both performance targets stated above, all unvested performance-based RSUs shall be forfeited. Additional detail relating to the performance-based RSU grant, will be provided to the Employee at a future date.
Annual LTI Award
Employee will be eligible to participate in the Company’s equity incentive plans for executives, beginning in 2023, and receive annual equity grants thereunder. The amount of Employee’s annual equity Long Term Incentive (“LTI”) value shall initially be equivalent to $500,000 at the time of the grant. At this time, the Company expects to grant LTI awards to qualified employees in January 2023. Employee’s participation in the executive equity incentive plan will be on terms consistent with the LTI program applicable to broader Enfusion executive team.
		10.
	Vacation. In accordance with Enfusion’s Flexible Time Off policy, which may be amended from time to time, Employee is entitled to Flexible Time Off as needed each calendar year. Flexible Time Off will not accrue or vest and therefore will not be paid out at the time of separation of employment.

		11.
	Notices to Employee.

[***]
​

​
	
	​
	Chicago
125 South Clark Street
Suite 750
Chicago, IL 60603
	​
enfusion.com

​
​

​

Acknowledged and Accepted:
By Employee
Signature: /s/ Oleg Movchan
Name: Oleg Movchan
Date: December 22, 2022

​
	
	​
	Chicago
125 South Clark Street
Suite 750
Chicago, IL 60603
	​
enfusion.com

​
​

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]